Original Article

High-Dose Atorvastatin after Stroke or Transient Ischemic Attack

The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators

N Engl J Med 2006; 355:549-559August 10, 2006

Abstract

Background

Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established.

Full Text of Background...

Methods

We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke.

Full Text of Methods...

Results

The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin.

Full Text of Results...

Conclusions

In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602.)

Full Text of Discussion...

Read the Full Article...

Media in This Article

Figure 1Screening, Enrollment, and Outcomes.

Figure 2Kaplan–Meier Curves for Stroke and TIA.

Article Activity

425 articles have cited this article

Article

Despite the efficacy of a variety of secondary preventive therapies, patients who have had a stroke or transient ischemic attack (TIA) remain at risk for stroke as well as coronary and other cardiovascular events.1 Therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) reduces the risk of stroke among patients with coronary heart disease and those at increased risk for cardiovascular disease.2-8 A meta-analysis of 90,000 patients included in these previous statin trials showed that the reduction in the risk of stroke was primarily related to the extent to which low-density lipoprotein (LDL) cholesterol levels were lowered.8 No data exist to show that statin treatment decreases the risk of stroke among patients with a history of stroke or TIA.9,10 The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial was designed to determine whether a daily dose of 80 mg of atorvastatin would reduce the risk of stroke in patients with no known coronary heart disease who had had a stroke or TIA within the previous six months.

Methods

The methods of the SPARCL study have been described in detail previously.11 The study was approved by the local research ethics committee or institutional review board at each participating center (15 of 205 centers excluded otherwise suitable patients with an LDL cholesterol level above 160 mg per deciliter [4.1 mmol per liter], as required by their institutional review boards), and all patients gave written informed consent.

Study Hypothesis and Patient Population

The primary hypothesis of the study was that treatment with 80 mg of atorvastatin per day would reduce the risk of fatal or nonfatal stroke among patients with a history of stroke or TIA. Eligible patients were men and women over 18 years of age who had had an ischemic or hemorrhagic stroke or a TIA (diagnosed by a neurologist within 30 days after the event) 1 to 6 months before randomization. Patients with hemorrhagic stroke were included if they were deemed by the investigator to be at risk for ischemic stroke or coronary heart disease. Stroke was defined by focal clinical signs of central nervous system dysfunction of vascular origin that lasted for at least 24 hours; TIA was defined by the loss of cerebral or ocular function for less than 24 hours, presumably owing to atherosclerotic causes. Patients had to be ambulatory, with a modified Rankin score of no more than 3 (scores can range from 0 to 6, with higher scores indicating more severe disability or death), and to have an LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter) and no more than 190 mg per deciliter (4.9 mmol per liter).12 The exclusion criteria, which have been described in detail previously, included atrial fibrillation, other cardiac sources of embolism, and subarachnoid hemorrhage.11 Patients were enrolled between September 1998 and March 2001.

Study Protocol

Patients who were taking lipid-altering drugs had to stop these medications 30 days before the screening phase of the study. Within 30 days after the initial screening visit, eligible patients were randomly assigned to double-blind therapy with either 80 mg of atorvastatin per day or placebo. To ensure that investigators remained unaware of a patient's treatment assignment on the basis of changes in LDL cholesterol levels during the study, if LDL cholesterol levels dropped below 40 mg per deciliter (1.0 mmol per liter) in a patient treated with atorvastatin, the investigator for a randomly chosen placebo patient was notified and LDL cholesterol levels were remeasured in both patients. All patients were counseled to follow the National Cholesterol Education Program Step 1 (or similar) diet throughout the study.13 Follow-up visits were scheduled one, three, and six months after enrollment and every six months thereafter. Surviving patients made their last study visit between March and June 2005.

Efficacy Outcomes

The primary outcome was the time from randomization to a first nonfatal or fatal stroke. There were seven prespecified secondary composite outcomes: stroke or TIA, major coronary event (death from cardiac causes, nonfatal myocardial infarction, or resuscitation after cardiac arrest), major cardiovascular event (stroke plus any major coronary event), acute coronary event (major coronary event or unstable angina), any coronary event (acute coronary event plus a coronary revascularization procedure, unstable angina, or angina or ischemia requiring emergency hospitalization), revascularization procedure (coronary, carotid, or peripheral), and any cardiovascular event (any of the former plus clinically significant peripheral vascular disease).11 Individual components of the composite end points and death from any cause were also prespecified secondary outcomes.

Safety Assessments

Full clinical laboratory assessments were performed and electrocardiograms were obtained and subsequently interpreted by a central laboratory at screening, at regular intervals during the study, and on completion of the study. Drug safety was assessed by an evaluation of the type, frequency, severity, and duration of any reported adverse event and on the basis of vital signs, physical examinations, and laboratory tests.

Statistical Analysis

The study was designed to have a statistical power of 90 percent to detect an absolute reduction of 25 percent in the primary end point in the atorvastatin group as compared with the placebo group during a median follow-up of five years with a two-sided significance level of P<0.05. Given the specified statistical power, the enrollment of 4200 patients, and an assumed annual rate of 3.5 percent for the primary end point in the placebo group, the study was designed to continue until 540 primary end points had occurred.

Seven interim analyses of efficacy were performed during the study, with a stopping boundary corresponding to a two-sided significance level of P=0.0001 for the first analysis and P=0.001 thereafter. Because of these interim analyses, the final P value had to be less than 0.048 to indicate a significant difference.

The analysis plan was prespecified and performed on an intention-to-treat basis with the inclusion of all patients who underwent randomization. Efficacy analyses were also performed according to the treatment actually received in a prespecified population consisting of a group of all randomized patients who had an entry event within six months before randomization, were compliant with the study treatment for at least six months after randomization, and did not start statin therapy that was not specified by the study until at least six months after randomization. Initially, the log-rank test was used to compare the time from randomization to the first occurrence of a particular event in the two groups. To account for baseline factors thought to be related to the risk of events, prespecified Cox proportional-hazards models were used to calculate treatment-related hazard ratios, 95 percent confidence intervals, and P values, with adjustment for geographic region, entry event (stroke or TIA), time since entry event (as a continuous variable), sex, and age at baseline (as a continuous variable). Five patients were excluded from the prespecified adjusted analyses because of missing data on the entry event (including one patient in the placebo group who had a nonfatal stroke followed by a fatal stroke). For a given composite outcome, deaths that were not included in the composite were treated as censoring events. Events that occurred after the prespecified end-of-study censoring date for each patient were not included in the analysis; inclusion of these events did not alter the inferences of the data presented. Lipid and lipoprotein levels in patients receiving treatment were determined in linear models with terms for treatment and month of measurement. The absolute reductions in risk and the numbers needed to treat were determined from five-year Kaplan–Meier rates. All P values were two-sided, with no adjustment for multiple testing.

The SPARCL steering committee developed the study protocol with the sponsor and takes responsibility for the data and data analyses. Medpace (Cincinnati) managed all data. Medpace, Charles River Laboratories Clinical Services (Brussels), and the sponsor provided site monitoring throughout the study. Two independent end-point committees (one for neurologic and one for cardiovascular end points) adjudicated all potential end points without knowledge of the patients' treatment status or cholesterol levels. A data and safety monitoring board with independent statistical support performed interim monitoring analyses for safety and efficacy.

Results

Of 6670 screened, eligible patients, 4731 (70.9 percent) fulfilled the inclusion criteria and underwent randomization (Figure 1Figure 1Screening, Enrollment, and Outcomes.). The median duration of follow-up was 4.9 years (range among survivors, 4.0 to 6.6). Among survivors, there was no significant difference in the number of patients in each treatment group lost to follow-up (P=0.42). More patients in the placebo group than in the atorvastatin group withdrew consent after randomization (P=0.07), permanently discontinued study treatment (20.2 percent vs. 15.4 percent of follow-up time for the primary end point, respectively; P=0.07), and began open-label, nonstudy statin therapy (7.5 percent vs. 1.0 percent of follow-up time for the primary end point, respectively; the net difference in statin use between groups was 78.1 percent). During the trial, the treatment assignment of nine patients (three assigned to atorvastatin and six assigned to placebo) was revealed to the study physician.

After randomization, the patients also took aspirin or other antiplatelet drugs (94.1 percent of patients in the placebo group and 93.6 percent of patients in the atorvastatin group); angiotensin-converting–enzyme inhibitors (46.8 percent and 46.9 percent, respectively); dihydropyridine derivatives (29.6 percent and 27.8 percent, respectively); beta-blockers (33.4 percent and 31.5 percent, respectively); angiotensin II–receptor antagonists (14.8 percent and 14.1 percent, respectively); vitamin K antagonists, including warfarin (12.4 percent and 12.2 percent, respectively); or open-label statins (25.4 percent and 11.4 percent, respectively). Atorvastatin was the most frequently used nonstudy, open-label statin in both study groups.

The mean (±SE) LDL cholesterol levels were similar in the two groups at baseline (Table 1Table 1Baseline Characteristics of the Patients.). One month after randomization, the LDL cholesterol level in the atorvastatin group had decreased to 61.3±0.4 mg per deciliter (1.58±0.01 mmol per liter) (a decrease of 53 percent, P<0.001) and was unchanged in the placebo group at 133.5±0.5 mg per deciliter (3.45±0.01 mmol per liter) (P=0.65). The mean lipid values during the course of the trial were as follows: LDL cholesterol, 72.9±0.5 mg per deciliter (1.89±0.01 mmol per liter) in the atorvastatin group, as compared with 128.5±0.5 mg per deciliter (3.32±0.01 mmol per liter) in the placebo group (P<0.001); high-density lipoprotein (HDL) cholesterol, 52.1±0.3 as compared with 51.0±0.3 mg per deciliter (1.35±0.01 vs. 1.32±0.01 mmol per liter), respectively (P=0.006); total cholesterol, 147.2±0.6 as compared with 208.4±0.6 mg per deciliter (3.81±0.02 vs. 5.39±0.02 mmol per liter), (P<0.001); and triglycerides, 111.5±1.3 as compared with 145.0±1.3 mg per deciliter (1.26±0.01 vs. 1.64±0.01 mmol per liter), respectively (P<0.001).

A primary end point (any nonfatal or fatal stroke) occurred in 265 patients in the atorvastatin group and 311 in the placebo group (unadjusted P=0.05) (Table 2Table 2Estimates of the Hazard Ratio for the Primary and Secondary Efficacy Outcome Measures.). The absolute difference in Kaplan–Meier rates at five years was 2.2 percent (95 percent confidence interval, 0.2 to 4.2 percent). A total of 136 patients in the placebo group and 154 patients in the atorvastatin group died from causes other than stroke before they could have a nonfatal stroke. After prespecified adjustment for baseline factors, atorvastatin was associated with a 16.0 percent relative reduction in the risk of nonfatal or fatal stroke (hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03) (Table 2 and Figure 2Figure 2Kaplan–Meier Curves for Stroke and TIA.). Prespecified analysis of 4162 patients according to the protocol showed an 18.0 percent relative reduction in the risk of stroke in the atorvastatin group, as compared with the placebo group (hazard ratio, 0.82; 95 percent confidence interval, 0.69 to 0.98; P=0.03).

Analysis of secondary end points showed reductions in the combined risk of stroke and TIA. The risk of cardiovascular events, including major coronary events and revascularization procedures, was reduced substantially (Table 2). There was no significant difference between treatment groups in overall mortality (including cancer-related mortality). Kaplan–Meier estimates for selected components of the secondary end points are given in Figure 3Figure 3Kaplan–Meier Curves for Coronary and Cardiovascular Events..

Post hoc analyses indicated significant differences in the treatment effect (hazard ratios) based on the type of stroke occurring during the trial (ischemic, hemorrhagic, or unclassified stroke) when the other types were treated as censoring events (P=0.01 by the likelihood-ratio test). The cause-specific adjusted hazard ratios in the atorvastatin group, as compared with the placebo group, were 0.78 (95 percent confidence interval, 0.66 to 0.94) for ischemic stroke, 1.66 (95 percent confidence interval, 1.08 to 2.55) for hemorrhagic stroke, and 0.55 (95 percent confidence interval, 0.21 to 1.40) for unclassified stroke. Of the 492 patients who had at least one ischemic stroke, 218 were in the atorvastatin group and 274 were in the placebo group; of the 88 patients who had at least one hemorrhagic stroke, 55 were in the atorvastatin group and 33 were in the placebo group; and of the 19 patients who had at least one unclassified stroke, 7 were in the atorvastatin group and 12 were in the placebo group. The incidence of fatal hemorrhagic stroke did not differ significantly between the groups (17 in the atorvastatin and 18 in the placebo group).

Safety assessments revealed no significant differences between groups in the incidence of serious adverse events (Table 3Table 3Incidence of Adverse Events and Elevated Laboratory Values.). There were five cases of rhabdomyolysis, two in the atorvastatin group and three in the placebo group. Persistent elevation of alanine or aspartate aminotransferase (>3 times the upper limit of the normal group on two consecutive occasions) was more frequent in the atorvastatin group (51 patients, or 2.2 percent) than in the placebo group (11 patients, or 0.5 percent; P<0.001 by the chi-square test). There were no cases of liver failure.

Discussion

This prospective, randomized, placebo-controlled trial demonstrated that treatment with 80 mg of atorvastatin per day reduced the risk of subsequent stroke in patients without known coronary heart disease and with LDL cholesterol levels of 100 to 190 mg per deciliter who had had a recent stroke or TIA. The study was not powered to assess the effect of treatment on the risk of death from any cause or on fatal and nonfatal stroke separately, but the risk of fatal stroke was significantly reduced. The reduction in the risk of nonfatal stroke was consistent with the treatment effect, but not significant.

Although at enrollment, patients had no known coronary heart disease, the risk of cardiovascular events, including major coronary events and revascularization procedures, was also substantially reduced. On the basis of our data, 46 patients (95 percent confidence interval, 24 to 243) would need to be treated for five years to prevent one stroke, 29 patients (95 percent confidence interval, 18 to 75) to prevent one major cardiovascular event, and 32 patients (95 percent confidence interval, 22 to 59) to avoid one revascularization procedure. These benefits were observed despite the increased use of open-label nonstudy statins during the study, a result suggesting that the effect is robust.

As expected, the beneficial effect of statin therapy on the risk of recurrent stroke was due to a reduction in the risk of cerebral infarction, the mechanism of which largely has been attributed to a reduction in LDL cholesterol levels.8 The lower average LDL cholesterol level achieved in the atorvastatin as compared with the placebo group is consistent with this hypothesis. Other putative mechanisms include a variety of possible pleiotropic effects.14

Our results contrast with those of the Heart Protection Study (HPS), which found no reduction in the risk of stroke among patients with prior cerebrovascular disease (10.4 percent of patients in the statin group had a recurrent stroke, as compared with 10.5 percent of patients in the placebo group).10 A possible explanation for this difference in results is that patients in the HPS were enrolled an average of 4.3 years after the index event, whereas the risk of recurrence is highest within the first years after stroke.10,15,16 Another explanation may be the larger reduction in LDL cholesterol in our study than in the HPS (56 mg per deciliter [1.4 mmol per liter] vs. 39 mg per deciliter [1.0 mmol per liter]).10 Other differences between the trials have been reviewed previously.9

Although patients with known coronary heart disease were excluded at baseline, 9.2 percent (434 patients) had a coronary event or a noncoronary revascularization procedure during the trial. Treatment with atorvastatin reduced the risk of these events. This observation adds to evidence from previous studies involving patients at increased risk for cardiovascular disease showing that statin treatment reduces atherosclerotic complications.2-7 Our results support the concept that from the standpoint of statin treatment, stroke or TIA should be considered a coronary heart disease risk equivalent.

In our study, the overall benefit in terms of the reduction in the risk of stroke was significant despite an increase in hemorrhagic stroke in the atorvastatin group. Statistical heterogeneity was observed in the effects of atorvastatin on ischemic and hemorrhagic stroke. An increase in the incidence of hemorrhagic stroke among patients with cerebrovascular disease treated with simvastatin (40 mg) was noted in the HPS.10 Epidemiologic studies have suggested an association between low cholesterol levels and brain hemorrhage.17-19 Statin trials conducted largely in patients without cerebrovascular disease have reduced LDL cholesterol levels to 70 mg per deciliter (1.8 mmol per liter) or below, with no increase in the incidence of hemorrhagic stroke.20-22 The small number of patients with brain hemorrhage at entry in our study precludes any meaningful conclusions regarding the relative risks and benefits of statin treatment in this population. The potential risk of recurrent hemorrhage should be considered when one is deciding whether to administer a statin to patients who have had a hemorrhagic stroke.

In conclusion, in patients with a recent stroke or TIA, treatment with 80 mg of atorvastatin per day decreased the risk of stroke, major coronary events, and revascularization procedures. These results support the initiation of atorvastatin treatment soon after a stroke or TIA.

Supported by Pfizer.

Dr. Amarenco reports having received consulting fees from AstraZeneca, Novartis, Pfizer, and Sanofi-Aventis; lecture fees from Otsuka Pharmaceutical and Pfizer; and grant support from Pfizer. Dr. Bogousslavsky reports having received consulting fees from Pfizer and grant support from Pfizer. Dr. Callahan reports having received consulting fees from Sanofi, lecture fees from Bristol-Myers Squibb and Sanofi, and grant support from Pfizer. Dr. Goldstein reports having received consulting fees from Pfizer, Bayer, AstraZeneca, Bristol-Myers Squibb/Sanofi, GlaxoSmithKline, Merck Research Laboratories, Johnson & Johnson Cordis, and Organon; lecture fees from Bayer; and grant support from AGA Medical, Boehringer Ingelheim, the National Institutes of Health, Pfizer, and the Department of Veterans Affairs. Dr. Hennerici reports having received grant support from Pfizer and Servier. Dr. Rudolph is an employee of Pfizer and reports owning stock in the company. Dr. Sillesen reports having received consulting fees from Sanofi-Aventis; lecture fees from AstraZeneca, Bristol-Myers Squibb, Merck, and Sanofi-Aventis; and grant support from Pfizer. Ms. Simunovic and Mr. Szarek are employees of Pfizer and report owning stock in the company. Dr. Welch reports having received consulting fees from Eisai, GlaxoSmithKline, Medpointe, AstraZeneca, NMT Medical, and Ortho-McNeil; lecture fees from GlaxoSmithKline; and grant support from Pfizer. Dr. Zivin reports having received consulting fees from Angel Pharmaceuticals, MEDACorp, MEDIACorp, Pfizer, and Sirex; and grant support from PhotoThera and Pfizer. No other potential conflict of interest relevant to this article was reported.

We are indebted to all the trial participants and the vast numbers of doctors, nurses, and hospital staff across the globe for their long-term commitment to the study; to Ellen Huang for her dedication and support; and to Sheila Auster, Sandra Brown, Marlen Castano, Lana De Weaver, Karen Ivanac, Sinde Krapf, Jaman Maroni, Scott McBride, James Nawrocki, Connie Newman, Lekan Odeleye, Bill Sasiela, Robert Sawyer, Heike Schwende, John Tsai, and Bernd Wagner (all at Pfizer) for their contributions.

Source Information

Pierre Amarenco, M.D. (Denis Diderot University, Paris), Julien Bogousslavsky, M.D. (University of Lausanne, Lausanne, Switzerland), Alfred Callahan, III, M.D. (Neurologic Consultants, Nashville), Larry B. Goldstein, M.D. (Duke University Medical Center, Durham, N.C.), Michael Hennerici, M.D., Ph.D. (Universitat Heidelberg, Mannheim, Germany), Amy E. Rudolph, Ph.D. (Pfizer, New York), Henrik Sillesen, M.D., D.M.Sc. (University of Copenhagen, Copenhagen), Lisa Simunovic, M.S. (Pfizer, New York), Michael Szarek, M.S. (Pfizer, New York), K.M.A. Welch, M.B., Ch.B., (Rosalind Franklin University of Medicine and Science, North Chicago), and Justin A. Zivin, M.D., Ph.D. (University of California, San Diego) assume full responsibility for the overall content and integrity of the article.

Address reprint requests to Dr. Welch at the Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd., North Chicago, IL 60064, or at michael.welch@rosalindfranklin.edu.

Other members of the SPARCL Study are listed in the Appendix.

Appendix

Participants in the SPARCL Study were as follows: Steering Committee — K.M.A. Welch (chair), A. Callahan, III, L.B. Goldstein, J. Zivin, United States; P. Amarenco, France; J. Bogousslavsky, Switzerland; M.G. Hennerici, Germany; H. Sillesen, Denmark; Publication Subcommittee — H. Sillesen, Denmark (chair); W. Clark, L.B. Goldstein, J. Zivin, United States; A. Dávalos, Spain; M. Kaste, Finland; L. Leiter, Canada; Retention Subcommittee — P. Amarenco (cochair), France; A. Callahan III (cochair), I. Altafullah, G. Graham, United States; J. Glahn, Germany; D. Jiménez Hernández, Spain; R. MacWalter, United Kingdom; R. Scott, New Zealand; A. Shuaib, Canada; J. Sivenius, Finland; R. Stipal, Czech Republic; Safety Committee — R. Hart (chair), J. Marsh, R. Sacco, United States; B. Norrving, Sweden; S. Pocock, United Kingdom; Cerebrovascular End-Point Committee — J. Easton (chair), J. Whisnant, United States; M. Brown, United Kingdom; Z. Nagy, Hungary; Cardiovascular End-Point Committee — B. O'Neill (chair), Canada; F. Kleber, Germany; J.-M. LaBlanche, France; F. Welty, United States; Investigators (number of randomized patients in parentheses) — Australia (167): D. Crimmins, S. Davis, S. Dimmitt, G. Donnan, J. Frayne, D. Freilich, A. Zagami; Austria (87): J. Mikocki, C. Schmidauer, R. Schmidt; Belgium (41): J. De Bleecker, F. Deceuninck, P. Tack, V. Thijs; Brazil (8): J. Gomes Fernandes; Canada (295): M. Beaudry, R. Cote, K. Hoyte, L.-H. Lebrun, A. Mackey, D. Sahlas, D. Selchen, A. Shuaib, J.D. Spence, P. Teal, M. Winger; Chile (10): G. Matamala; Czech Republic (222): R. Cifkova, Z. Kalita, I. Rektor, H. Rosolova, R. Stipal, D. Vaclavik; Denmark (57): G. Boysen, H. Iversen, H. Klingenberg, H. Sillesen; Finland (385): M. Hillbom, M. Kaste, H. Numminen, A. Pilke, A. Salmivaara, J. Sivenius; France (161): S. Alamowitch, P. Amarenco, J. Boulliat, T. De Broucker, F. Chollet, M.-H. Mahagne, L. Milandre, T. Moulin; Germany (284): U. Bogdahn, H.-C. Diener, M. Dichgans, J. Glahn, R. Haberl, L. Harms, M.G. Hennerici, S. Knecht, G. Kroczek, C. Lichy, D. Sander, D. Schneider; Greece (39): C. Karageorgiou, A. Kazis, I. Milonas, P. Stathis, D. Vogiatzoglou; Israel (61): N. Bornstein, S. Honigman, Y. Lampl, J. Streifler; Italy (75): A. Capurso, G. Comi, C. Ferrarese, C. Gandolfo, M. Poloni, U. Senin; Mexico (9): R. Rangel Guerra; Netherlands (171): A.M. Boon, J.H.A. De Keyser, P.L.M. De Kort, J.A. Haas, D.J. Kamphuis, P.-J. Koudstaal; New Zealand (219): N. Anderson, R. Scott, G. Singh; Poland (249): A. Czlonkowska, W. Drozdowski, Z. Gralewski, W. Kozubski, A. Kuczynska-Zardzewialy, R. Podemski, Z. Stelmasiak, A. Szczudlik; Portugal (102): C. Da Costa Correia, J. Ferro, L. Salgueiro e Cunha; Slovakia (37): J. Lietava, K. Raslova; South Africa (93): J. Carr, J. Gardiner, A. Kruger; Spain (744): J. Alvarez-Sabin, A. Chamorro, E. Diez-Tejedor, O. Fernández, J. Trejo Gabriel y Galán, J. González Marcos, J. Egido Herrero, M. Jiménez Martínez, A. Lago Martin, E. Mostacero Miguel, J. Vivancos Mora, J. Moltó, J. Viguera Romero, E. Cuartero Rodriguez, F. Rubio, J. Serena; Sweden (121): A.C. Laska, B. Leijd, T. Strand, A. Terent, A. Waegner, T. Wallén; Switzerland (86): R. Baumgartner, J. Bogousslavsky, H. Hungerbühler, P. Lyrer, H. Mattle; United Kingdom (146): P.M. Bath, E.B. Ekpo, A. Freeman, K.R. Lees, M.J. MacLeod, R.S. MacWalter, A.K. Sharma, H.G.M. Shetty; United States (853): G. Albers, I. Altafullah, O. Benavente, D. Book, J. Broderick, C. Calder, A. Callahan III, W. Carlini, S. Chaturvedi, T. Chippendale, W. Clark, B. Coull, P. Davis, T. Devlin, A. Dick, G. Dooneief, R. Duff, N. Estronza, A. Forteza, M. Frankel, J. Frey, G. Friday, J. Goldstein, G. Graham, M. Hammer, W. Harper, J. Harris, B. Hendin, D. Hess, R. Hinton, J. Hollander, R. Hughes, S. Kasner, T. Kent, L. Kim, H. Kirshner, M. LaMonte, L. Ledbetter, P. Lee-Kwen, K. Levin, R. Libman, J. Matlock, P. McDowell, F. McGee Jr., B. Meyer, A. Minagar, M. Moussouttas, R. Munson, M. Nash, A. Nassief, S. Orr, G. Ratinov, V. Salanga, S. Silliman, R. Singer, D. Smith, H. Sullivan, G. Tietjen, D. Thaler, M. Tuchman, D. Uskavitch, P. Verro, R. Vicari, R. Weinstein, J. Wilterdink, R. Zweifler; Venezuela (9): M. De Bastos.

References

References

1. 1

   Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:577-617
   CrossRef | Web of Science | Medline

2. 2

   Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389
   Web of Science | Medline

3. 3

   The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357
   Full Text | Web of Science | Medline

4. 4

   Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999;99:216-223
   Web of Science | Medline

5. 5

   Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158
   CrossRef | Web of Science | Medline

6. 6

   Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
   CrossRef | Web of Science | Medline

7. 7

   Heart Protection Collaborative Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   CrossRef | Web of Science | Medline

8. 8

   Amarenco P, Labreuche J, Lavallee P, Touboul P-J. Statins in stroke prevention and carotid atherosclerosis: systematic review and meta-analysis. Stroke 2004;35:2902-2909
   CrossRef | Web of Science | Medline

9. 9

   Goldstein LB, Amarenco P, Bogousslavsky J, et al. Statins for secondary stroke prevention in patients without known coronary heart disease: the jury is still out. Cerebrovasc Dis 2004;18:1-2
   CrossRef | Web of Science | Medline

10. 10

    Heart Protection Collaborative Study Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767
    CrossRef | Web of Science | Medline

11. 11

    Amarenco P, Bogousslavsky J, Callahan AS, et al. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis 2003;16:389-395[Erratum, Cerebrovasc Dis 2004;17:91-2.]
    CrossRef | Web of Science | Medline

12. 12

    Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957;2:200-215
    Medline

13. 13

    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
    CrossRef | Web of Science

14. 14

    Amarenco P, Lavallee PC, Touboul P-J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004;3:271-278
    CrossRef | Web of Science | Medline

15. 15

    Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 2002;33:901-906
    CrossRef | Web of Science | Medline

16. 16

    Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004;35:731-735
    CrossRef | Web of Science | Medline

17. 17

    Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989;320:904-910
    Full Text | Web of Science | Medline

18. 18

    Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989;20:1460-1465
    CrossRef | Web of Science | Medline

19. 19

    Lee S-H, Bae H-J, Yoon B-W, Kim H, Kim D-E, Roh J-K. Low concentration of serum total cholesterol is associated with multifocal signal loss lesions on gradient-echo magnetic resonance imaging: analysis of risk factors for multifocal signal loss lesions. Stroke 2002;33:2845-2849
    CrossRef | Web of Science | Medline

20. 20

    Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005;46:1411-1416[Erratum, J Am Coll Cardiol 2006;47:472.]
    CrossRef | Web of Science | Medline

21. 21

    Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002;106:1690-1695
    CrossRef | Web of Science | Medline

22. 22

    Waters DD, LaRosa JC, Barter P, et al. Effects of intensive lipid lowering with atorvastatin on cerebrovascular events in patients with stable coronary disease: a Treating to New Targets (TNT) substudy. Circulation 2005;112:Suppl 1:2020-2020
    

Citing Articles (425)

Citing Articles

1. 1

   K. Rahimi, W. Majoni, A. Merhi, J. Emberson. (2012) Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials. European Heart Journal
   CrossRef

2. 2

   Ángel Cequier, César Carrascosa, Exuperio Diez-Tejedor, Marian Goicoechea, Alejandro González-García, Juan Quiles, Rafael Ruiz-Salmerón, Vicenç Riambau, Ángel Alonso, Manuel Anguita, Josep Comín, Antonio Fernández-Ortiz, Manuel Pan, Fernando Worner. (2012) Comentarios a la guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de las enfermedades arteriales periféricas. Un informe del Grupo de Trabajo del Comité de Guías de Práctica Clínica de la Sociedad Española de Cardiología. Revista Española de Cardiología 65:2, 119-124
   CrossRef

3. 3

   Michel Tendera, Victor Aboyans, Marie-Louise Bartelink, Iris Baumgartner, Denis Clément, Jean-Philippe Collet, Alberto Cremonesi, Marco De Carlo, Raimund Erbel, F. Gerry R. Fowkes, Magda Heras, Serge Kownator, Erich Minar, Jan Ostergren, Don Poldermans, Vincent Riambau, Marco Roffi, Joachim Röther, Horst Sievert, Marc van Sambeek, Thomas Zeller. (2012) Guía de práctica clíníca de la ESC sobre diagnóstico y tratamiento de las enfermedades arteriales periféricas. Revista Española de Cardiología 65:2, 172.e1-172.e57
   CrossRef

4. 4

   Angel Cequier, Cesar Carrascosa, Exuperio Diez-Tejedor, Marian Goicoechea, Alejandro Gonzalez-Garcia, Juan Quiles, Rafael Ruiz-Salmeron, Vicenc Riambau, Angel Alonso, Manuel Anguita, Josep Comin, Antonio Fernandez-Ortiz, Manuel Pan, Fernando Worner. (2012) Comments on the ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases. A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Española de Cardiología (English Edition) 65:2, 119-124
   CrossRef

5. 5

   G. Danaei, M. Tavakkoli, M. A. Hernan. (2012) Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of Statins. American Journal of Epidemiology
   CrossRef

6. 6

   Cassandra D. Benge, Brandon Markley, Michael Shawn McFarland. (2012) Role of Aggressive LDL Reduction in Patients With Coronary Heart Disease. Southern Medical Journal 105:1, 48-55
   CrossRef

7. 7

   Noriko Makihara, Yasushi Okada, Masatoshi Koga, Yoshiaki Shiokawa, Jyoji Nakagawara, Eisuke Furui, Kazumi Kimura, Hiroshi Yamagami, Yasuhiro Hasegawa, Kazuomi Kario, Satoshi Okuda, Masaki Naganuma, Kazunori Toyoda. (2012) Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry. Cerebrovascular Diseases 33:3, 240-247
   CrossRef

8. 8

   Jin M. Jung, Yong Yang, Dong H. Lee, Greg Fridman, Alexander Fridman, Young I. Cho. (2011) Effect of Dielectric Barrier Discharge Treatment of Blood Plasma to Improve Rheological Properties of Blood. Plasma Chemistry and Plasma Processing
   CrossRef

9. 9

   William J. Powers. (2011) Management of Patients With Atherosclerotic Carotid Occlusion. Current Treatment Options in Neurology 13:6, 608-615
   CrossRef

10. 10

    (2011) Guía de la ESC/EAS sobre el manejo de las dislipemias. Revista Española de Cardiología 64:12, 1168.e1-1168.e60
    CrossRef

11. 11

    Adnan H. Siddiqui, Sabareesh K. Natarajan, L. Nelson Hopkins, Elad I. Levy. (2011) Carotid Artery Stenting for Primary and Secondary Stroke Prevention. World Neurosurgery 76:6, S40-S59
    CrossRef

12. 12

    Rodrigo Antonini Ribeiro, Patricia Klarmann Ziegelmann, Bruce Bartholow Duncan, Steffan Frosi Stella, José Luiz da Costa Vieira, Luciane Maria Fabian Restelatto, Emílio Hideyuki Moriguchi, Carisi Anne Polanczyk. (2011) Impact of statin dose on major cardiovascular events: A mixed treatment comparison meta-analysis involving more than 175,000 patients. International Journal of Cardiology
    CrossRef

13. 13

    Maria Concetta Cataldo, Maria Luisa Calcara, Giuseppe Caputo, Caterina Mammina. (2011) Association of total serum cholesterol with functional outcome following home care rehabilitation in Italian patients with stroke. Disability and Health Journal
    CrossRef

14. 14

    Michael Reinert, Marie-Louise Mono, Dominique Kuhlen, Luigi Mariani, Alain Barth, Jürgen Beck, Robert H. Andres, Jan Gralla, Rolf Wymann, Jürgen Schmidt, Christin Kauert, Gerhard Schroth, Marcel Arnold, Heinrich P. Mattle, Andreas Raabe, Urs Fischer. (2011) Restenosis after microsurgical non-patch carotid endarterectomy in 586 patients. Acta Neurochirurgica
    CrossRef

15. 15

    , , M. Tendera, V. Aboyans, M.-L. Bartelink, I. Baumgartner, D. Clement, J.-P. Collet, A. Cremonesi, M. De Carlo, R. Erbel, F. G. R. Fowkes, M. Heras, S. Kownator, E. Minar, J. Ostergren, D. Poldermans, V. Riambau, M. Roffi, J. Rother, H. Sievert, M. van Sambeek, T. Zeller, , J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , P. Kolh, A. Torbicki, S. Agewall, A. Blinc, M. Bulvas, F. Cosentino, T. De Backer, A. Gottsater, D. Gulba, T. J. Guzik, B. Jonsson, G. Kesmarky, A. Kitsiou, W. Kuczmik, M. L. Larsen, J. Madaric, J.-L. Mas, J. J. V. McMurray, A. Micari, M. Mosseri, C. Muller, R. Naylor, B. Norrving, O. Oto, T. Pasierski, P.-F. Plouin, F. Ribichini, J.-B. Ricco, L. Ruilope, J.-P. Schmid, U. Schwehr, B. G. M. Sol, M. Sprynger, C. Tiefenbacher, C. Tsioufis, H. Van Damme. (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 32:22, 2851-2906
    CrossRef

16. 16

    Majid M Mughal, Mohsin K Khan, J Kevin DeMarco, Arshad Majid, Fadi Shamoun, George S Abela. (2011) Symptomatic and asymptomatic carotid artery plaque. Expert Review of Cardiovascular Therapy 9:10, 1315-1330
    CrossRef

17. 17

    Emma Heeley, Craig Anderson, Anushka Patel, Alan Cass, David Peiris, Andrew Weekes, John Chalmers. (2011) Disparities between prescribing of secondary prevention therapies for stroke and coronary artery disease in general practice. International Journal of Strokeno-no
    CrossRef

18. 18

    Christopher Beer, David Blacker, Michael Bynevelt, Graeme J. Hankey, Ian B. Puddey. (2011) A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. International Journal of Strokeno-no
    CrossRef

19. 19

    M. Alberton, P. Wu, E. Druyts, M. Briel, E. J. Mills. (2011) Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM
    CrossRef

20. 20

    D. K. Y. Chan, F. O’Rourke, Q. Shen, J. C. S. Mak, W. T. Hung. (2011) Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurologica Scandinavica 124:3, 188-195
    CrossRef

21. 21

    Andreas Charidimou, David J Werring. (2011) Cerebral microbleeds: detection, mechanisms and clinical challenges. Future Neurology 6:5, 587-611
    CrossRef

22. 22

    S. ACHTERBERG, F. L. J. VISSEREN, L. J. KAPPELLE, D. M. O. PRUISSEN, Y. VAN DER GRAAF, A. ALGRA, . (2011) Differential propensity for major hemorrhagic events in patients with different types of arterial disease. Journal of Thrombosis and Haemostasis 9:9, 1724-1729
    CrossRef

23. 23

    David Preiss, Naveed Sattar. (2011) Statins and the risk of new-onset diabetes. Current Opinion in Lipidology1
    CrossRef

24. 24

    B. Fuentes, J. Gallego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (I). Actuación sobre los factores de riesgo y estilo de vida. Neurología
    CrossRef

25. 25

    Anna Russolillo, Matteo Nicola Dario Di Minno, Antonella Tufano, Domenico Prisco, Giovanni Di Minno. (2011) Filling the gap between science & clinical practice: Prevention of stroke recurrence. Thrombosis Research
    CrossRef

26. 26

    Alessandro Squizzato, Erica Romualdi, Francesco Dentali, Walter Ageno, Alessandro Squizzato. 2011. Statins for acute ischemic stroke. .
    CrossRef

27. 27

    H.J. Audebert. (2011) Schlaganfallbehandlung 2011. Notfall + Rettungsmedizin 14:5, 413-424
    CrossRef

28. 28

    M. Endres, M. Grond, W. Hacke, M. Ebinger, P.D. Schellinger, M. Dichgans. (2011) Grenzentscheidungen in der Schlaganfalltherapie. Der Nervenarzt 82:8, 957-972
    CrossRef

29. 29

    Robert A. Taylor, John B. Weigele, Scott E. Kasner. (2011) Current Management of Symptomatic Intracranial Stenosis. Current Atherosclerosis Reports 13:4, 321-329
    CrossRef

30. 30

    Sharon Poisson, S. Claiborne Johnston. (2011) Prevention of Stroke Following Transient Ischemic Attack. Current Atherosclerosis Reports 13:4, 330-337
    CrossRef

31. 31

    Dominique Deplanque, Pierre Amarenco. (2011) Blood Lipids and Stroke: What More Can We Do Besides Reducing Low-Density Lipoprotein Cholesterol?. Current Atherosclerosis Reports 13:4, 306-313
    CrossRef

32. 32

    Osman Kozak, Nauman Tariq, M Fareed K Suri, Robert A Taylor, Adnan I Qureshi. (2011) High Risk of Recurrent Ischemic Events Among Patients With Deferred Intracranial Angioplasty and Stent Placement for Symptomatic Intracranial Atherosclerosis. Neurosurgery 69:2, 334-343
    CrossRef

33. 33

    Murray Flaster, Sarkis Morales-Vidal, Michael J Schneck, José Biller. (2011) Statins in hemorrhagic stroke. Expert Review of Neurotherapeutics 11:8, 1141-1149
    CrossRef

34. 34

    , , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
    CrossRef

35. 35

    Junya Aoki, Ken Uchino. (2011) Treatment of Risk Factors to Prevent Stroke. Neurotherapeutics 8:3, 463-474
    CrossRef

36. 36

    Robert D. Safian. (2011) Treatment Strategies for Carotid Stenosis in Patients at Increased Risk for Surgery. Progress in Cardiovascular Diseases 54:1, 22-28
    CrossRef

37. 37

    Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
    CrossRef

38. 38

    Deborah A. Levine, Kenneth M. Langa. (2011) Vascular Cognitive Impairment: Disease Mechanisms and Therapeutic Implications. Neurotherapeutics 8:3, 361-373
    CrossRef

39. 39

    Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
    CrossRef

40. 40

    Navdeep Sangha, Nicole R. Gonzales. (2011) Treatment Targets in Intracerebral Hemorrhage. Neurotherapeutics 8:3, 374-387
    CrossRef

41. 41

    Janet van Kuilenburg, Knut Tore Lappegård, Joe Sexton, Izabela Plesiewicz, Paul Lap, Leon Bouwels, Tom Sprong, Tom Eirik Mollnes, Freek Verheugt, Waander L. van Heerde, Gheorghe A. Pop. (2011) Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. Journal of Clinical Lipidology 5:4, 273-280
    CrossRef

42. 42

    Genovefa Kolovou, Vana Kolovou, Ioannis Vasiliadis, Anthony S Wierzbicki, Dimitri P Mikhailidis. (2011) Ideal lipid profile and genes for an extended life span. Current Opinion in Cardiology 26:4, 348-355
    CrossRef

43. 43

    Marc I. Chimowitz, Michael J. Lynn, Tanya N. Turan, David Fiorella, Bethany F. Lane, Scott Janis, Colin P. Derdeyn. (2011) Design of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial. Journal of Stroke and Cerebrovascular Diseases 20:4, 357-368
    CrossRef

44. 44

    Antonio Muscari, Giovanni M. Puddu, Nadia Santoro, Claudia Serafini, Andrea Cenni, Valentina Rossi, Marco Zoli. (2011) The Atorvastatin During Ischemic Stroke Study. Clinical Neuropharmacology 34:4, 141-147
    CrossRef

45. 45

    S. Agewall. (2011) The large clinical statin trials. International Journal of Cardiology 150:1, 108-111
    CrossRef

46. 46

    Kyra Becker, Pat Tanzi, Angela Kalil, Dean Shibata, Kevin Cain. (2011) Early Statin Use is Associated with Increased Risk of Infection after Stroke. Journal of Stroke and Cerebrovascular Diseases
    CrossRef

47. 47

    Deborah Bergman. (2011) Preventing recurrent cerebrovascular events in patients with stroke or transient ischemic attack: The current data. Journal of the American Academy of Nurse Practitionersno-no
    CrossRef

48. 48

    Sergi Martinez-Ramirez, Raquel Delgado-Mederos, Rebeca Marín, Marc Suárez-Calvet, María Pilar Sáinz, Aída Alejaldre, Ángela Vidal-Jordana, Josep Lluís Martí-Vilalta, Joan Martí-Fàbregas. (2011) Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case–control study and a meta-analysis. Journal of Neurology
    CrossRef

49. 49

    Joshua Z. Willey, Mitchell S. V. Elkind. (2011) Stroke: Do statins improve outcomes after acute ischemic stroke?. Nature Reviews Neurology 7:7, 364-365
    CrossRef

50. 50

    Bernhard Föger. (2011) Lipid lowering therapy in type 2 diabetes. Wiener Medizinische Wochenschrift 161:11-12, 289-296
    CrossRef

51. 51

    Hisato Takagi, Takuya Umemoto. (2011) Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol. International Journal of Cardiology 149:2, 267-269
    CrossRef

52. 52

    Ahmed Alhusban, Susan C. Fagan. (2011) Secondary Prevention of Stroke in the Elderly: A Review of the Evidence. The American Journal of Geriatric Pharmacotherapy 9:3, 143-152
    CrossRef

53. 53

    Chi Chiu Mok, Chun Kwok Wong, Chi Hung To, Judy Po Shan Lai, Cheuk Sum Lam. (2011) Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care & Research 63:6, 875-883
    CrossRef

54. 54

    Atte Meretoja, Markku Kaste, Risto O Roine, Merja Juntunen, Miika Linna, Matti Hillbom, Reijo Marttila, Terttu Erilä, Aimo Rissanen, Juhani Sivenius, Unto Häkkinen. (2011) Trends in treatment and outcome of stroke patients in Finland from 1999 to 2007. PERFECT Stroke, a nationwide register study. Annals of Medicine 43:S1, S22-S30
    CrossRef

55. 55

    Ugo Paliani, Stefano Ricci. (2011) The role of statins in stroke. Internal and Emergency Medicine
    CrossRef

56. 56

    Gregory G. Schwartz, Bernard R. Chaitman, Jeffrey J. Goldberger, Michael Messig. (2011) High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. American Heart Journal 161:5, 993-999
    CrossRef

57. 57

    Jorge Humberto Tapia-Pérez, Elmar Kirches, Christian Mawrin, Raimund Firsching, Thomas Schneider. (2011) Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemotherapy and Pharmacology 67:5, 1193-1201
    CrossRef

58. 58

    Jonathan A. Rapp, Anil Verma, Tyrone J. Collins. 2011. Intracranial Vertebral Artery Stenting. , 427-435.
    CrossRef

59. 59

    George Howard, David C. Goff. (2011) Lipids and stroke: Looking for risk in all the wrong places?. Annals of Neurology 69:4, 597-599
    CrossRef

60. 60

    Islam Ahmed, Abdullah Jibawi, Mohamed Barkat, Karim El Sakka, Syed Waquar Yusuf. (2011) Management of carotid artery disease in the elderly. Aging Health 7:2, 321-333
    CrossRef

61. 61

    Liam Hirt, Alison Halliday. (2011) Controversies in neurology: asymptomatic carotid stenosis—intervention or just stick to medical therapy. The argument for carotid endarterectomy. Journal of Neural Transmission 118:4, 631-636
    CrossRef

62. 62

    Anette Varbo, Børge G. Nordestgaard, Anne Tybjaerg-Hansen, Peter Schnohr, Gorm B. Jensen, Marianne Benn. (2011) Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Annals of Neurology 69:4, 628-634
    CrossRef

63. 63

    David D. Waters, Jennifer E. Ho, David A. DeMicco, Andrei Breazna, Benoit J. Arsenault, Chuan-Chuan Wun, John J. Kastelein, Helen Colhoun, Philip Barter. (2011) Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin. Journal of the American College of Cardiology 57:14, 1535-1545
    CrossRef

64. 64

    L.A. Rodríguez de Antonio, P. Martínez-Sánchez, M.M. Martínez-Martínez, R. Cazorla-García, I. Sanz-Gallego, B. Fuentes, E. Díez-Tejedor. (2011) Tratamiento previo con estatinas y riesgo de complicaciones infecciosas tras un infarto cerebral agudo. Neurología 26:3, 150-156
    CrossRef

65. 65

    M. Endres, P. U. Heuschmann, U. Laufs, A. M. Hakim. (2011) Primary prevention of stroke: blood pressure, lipids, and heart failure. European Heart Journal 32:5, 545-552
    CrossRef

66. 66

    M. Ruiz-Bailén, J. Pérez-Valenzuela, A. Ferrezuelo-Mata, R.J. Obra-Cuadra. (2011) Efecto de la administración de las estatinas en la patología crítica no cardiológica. Medicina Intensiva 35:2, 107-116
    CrossRef

67. 67

    David J Collier, Neil R Poulter, Björn Dahlöf, Peter S Sever, Hans Wedel, Jan Buch, Mark J Caulfield. (2011) Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. Journal of Hypertension 29:3, 592-599
    CrossRef

68. 68

    E. J. Mills, P. WU, G. Chong, I. Ghement, S. Singh, E. A. Akl, O. Eyawo, G. Guyatt, O. Berwanger, M. Briel. (2011) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM 104:2, 109-124
    CrossRef

69. 69

    Pratik Bhattacharya, Seemant Chaturvedi. (2011) Intensive Medical Therapy for Asymptomatic Carotid Artery Stenosis. Current Cardiology Reports 13:1, 18-23
    CrossRef

70. 70

    Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Journal of the American College of Cardiology 57:8, 1002-1044
    CrossRef

71. 71

    Bas van den Bogaard, Bert-Jan H. van den Born, Rana Fayyad, David D. Waters, David A. DeMicco, John C. LaRosa, John J. P. Kastelein, Ingar Holme, . (2011) On-treatment lipoprotein components and risk of cerebrovascular events in the Treating to New Targets study. European Journal of Clinical Investigation 41:2, 134-142
    CrossRef

72. 72

    Andres Pineda, Luigi X. Cubeddu. (2011) Statin Rebound or Withdrawal Syndrome: Does It Exist?. Current Atherosclerosis Reports 13:1, 23-30
    CrossRef

73. 73

    Vincent Prinz, Matthias Endres. (2011) Statins and stroke: prevention and beyond. Current Opinion in Neurology 24:1, 75-80
    CrossRef

74. 74

    Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
    CrossRef

75. 75

    Vincent V. Truong, Alex Abou-Chebl. (2011) Interventional Management of Asymptomatic Extracranial Carotid Stenosis. Current Cardiology Reports 13:1, 30-37
    CrossRef

76. 76

    Michael Broukhim, Jonathan L. Halperin. (2011) Stroke Prevention in the High-risk Atrial Fibrillation Patient: Medical Management. Current Cardiology Reports 13:1, 9-17
    CrossRef

77. 77

    Davinia Ryan, Joseph Harbison. (2011) Stroke as a medical emergency in older people. Reviews in Clinical Gerontology 21:01, 45-54
    CrossRef

78. 78

    Martin M. Brown, David Doig. (2011) Carotid Stenting Versus Endarterectomy. Annual Review of Medicine 63:1, 110301100719093
    CrossRef

79. 79

    Halvor Næss, Ulrike Waje-Andreassen, Jan Brøgger, Lars Thomassen. (2011) Pasienter med akutt hjerneinfarkt innlagt i slagenhet. Tidsskrift for Den norske legeforening 131:8, 814-818
    CrossRef

80. 80

    Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Salas, Antonio Hernández Mijares, Vincent J. Carey, Michel P. Hermans, Frank M. Sacks, Jean-Charles Fruchart. (2011) The REALIST (REsiduAl risk, LIpids and Standard Therapies) study: an analysis of residual risk attributable to lipid profile in acute coronary syndrome. Endocrinología y Nutrición (English Edition) 58:1, 38-47
    CrossRef

81. 81

    Ken Miura, Yasuhiro Yoshii, Yoshikazu Nakamura, Ken Ikeda. (2011) Clinicoradiological Profile and Serum Lipid Levels of Intracerebral Hemorrhage in Prior Statin Users. Internal Medicine 50:13, 1385-1391
    CrossRef

82. 82

    K. Chwojnicki, A. Yagensky, L. Wierucki, I. Sichkaruk, N. Sydor, W.M. Nyka, B. Wyrzykowski, T. Zdrojewski. (2011) Assessment of the Quality of Secondary Ischemic Stroke Prevention in Selected Urban Areas of Poland and Ukraine: The ASCEP Study Results. European Neurology 65:6, 323-331
    CrossRef

83. 83

    Yasuhiro Nishiyama, Masayuki Ueda, Toshiaki Otsuka, Ken-ichiro Katsura, Arata Abe, Hiroshi Nagayama, Yasuo Katayama. (2011) Statin Treatment Decreased Serum Asymmetric Dimethylarginine (ADMA) Levels in Ischemic Stroke Patients. Journal of Atherosclerosis and Thrombosis 18:2, 131-137
    CrossRef

84. 84

    S. Goto. (2011) Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion: An old question revisited. Thrombosis and Haemostasis 106:2, 187-188
    CrossRef

85. 85

    Antonio García-Ríos, Javier Delgado-Lista, Pablo Pérez Martínez, Francisco Fuentes-Jiménez, Francisco Pérez-Jiménez, José López-Miranda. (2011) Eficacia de las estatinas en el manejo de la dislipemia. Un paso adelante. Revista Española de Cardiología Suplementos 11, 14-20
    CrossRef

86. 86

    Enrique C. Morales-Villegas, Germano Di Sciascio, Carlo Briguori. (2011) Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins. International Journal of Hypertension 2011, 1-12
    CrossRef

87. 87

    Kenzo Sakurai, Kenji Isahaya, Satoshi Takaishi, Bunta Kato, Kanako Shimizu, Kana Shimomura, Yoshiaki Tokuyama, Yasuhiro Hasegawa. (2011) Effects of early statin treatment on inflammatory biomarkers and clinical deterioration in patients with acute ischemic stroke. Rinsho Shinkeigaku 51:1, 6-13
    CrossRef

88. 88

    Y. Bjot, M. Giroud, E. Touz. (2011) Prevencin de los accidentes cerebrovasculares. EMC - Tratado de Medicina 15:1, 1-8
    CrossRef

89. 89

    Keun-Sik Hong. (2011) Measuring and Analysis of Outcome in Stroke Trials. Korean Journal of Stroke 13:1, 1
    CrossRef

90. 90

    Hiromi Kawai, Shoko Deguchi, Kentaro Deguchi, Toru Yamashita, Yasuyuki Ohta, Jingwei Shang, Fengfeng Tian, Xuemei Zhang, Ning Liu, Wentao Liu, Yoshio Ikeda, Tohru Matsuura, Koji Abe. (2011) Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Research 1368, 317-323
    CrossRef

91. 91

    Narayanaswamy Venketasubramanian, Joachim Röther, Deepak L. Bhatt, Blandine Pasquet, Jean-Louis Mas, Mark J. Alberts, Michael D. Hill, Franz Aichner, P. Gabriel Steg. (2011) Two-Year Vascular Event Rates in Patients with Symptomatic Cerebrovascular Disease: The REACH Registry. Cerebrovascular Diseases 32:3, 254-260
    CrossRef

92. 92

    Vivencio Barrios Alonso, Carlos Escobar Cervantes. (2011) Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. Revista Española de Cardiología Suplementos 11, 29-35
    CrossRef

93. 93

    Lina Badimon, Gemma Vilahur. (2011) Beneficio clínico de las estatinas: ¿hemos cubierto todo el espectro?. Revista Española de Cardiología Suplementos 11, 3-13
    CrossRef

94. 94

    Giovanni Corso, Edo Bottacchi, Adriana Brusa, Chiara Lia, Susanna Cordera, Guido Giardini, Massimo Pesenti Campagnoni, Massimo Veronese Morosini. (2011) Blood C-Reactive Protein Concentration with ABCD² Is a Better Prognostic Tool than ABCD² Alone. Cerebrovascular Diseases 32:2, 97-105
    CrossRef

95. 95

    Y. Bejot, A. Chantegret, D. Ben Salem, G.-V. Osseby, M. Giroud, M. Freysz. (2011) Gestione degli accidenti vascolari cerebrali in urgenza. EMC - Urgenze 15:2, 1-21
    CrossRef

96. 96

    Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor, Alice K. Jacobs, Sidney C. Smith, Jeffery L. Anderson, Cynthia D. Adams, Nancy Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Sharon Ann Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, Barbara Riegel, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. Catheterization and Cardiovascular Interventionsn/a-n/a
    CrossRef

97. 97

    Shinichiro Uchiyama, Yasuo Ikeda, Yasuhisa Urano, Yoshiharu Horie, Takenori Yamaguchi. (2011) The Japanese Aggrenox (Extended-Release Dipyridamole plus Aspirin) Stroke Prevention versus Aspirin Programme (JASAP) Study: A Randomized, Double-Blind, Controlled Trial. Cerebrovascular Diseases 31:6, 601-613
    CrossRef

98. 98

    Richard M. Zweifler, Leslie A. McClure, Virginia J. Howard, Mary Cushman, Martha K. Hovater, Monika M. Safford, George Howard, David C. Goff, Jr.. (2011) Racial and Geographic Differences in Prevalence, Awareness, Treatment and Control of Dyslipidemia: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Neuroepidemiology 37:1, 39-44
    CrossRef

99. 99

    Daniel S. Schöni, Serge Bogni, Amadé Bregy, Amina Wirth, Andreas Raabe, Istvan Vajtai, Uwe Pieles, Michael Reinert, Martin Frenz. (2011) Nanoshell assisted laser soldering of vascular tissue. Lasers in Surgery and Medicinen/a-n/a
    CrossRef

100. 100

     M.G. Hennerici. (2011) Report of the 20th European Stroke Conference, Hamburg, May 24–27, 2011. Cerebrovascular Diseases 32:6, 589-613
     CrossRef

101. 101

     Natalie J. Carter. (2010) Rosuvastatin. American Journal Cardiovascular Drugs 10:6, 383-400
     CrossRef

102. 102

     Joseph E. Thomas, Andrew M. Tershakovec, Charlotte Jones-Burton, Reza A. Sayeed, JoAnne M. Foody. (2010) Lipid Lowering for Secondary Prevention of Cardiovascular Disease in Older Adults. Drugs & Aging 27:12, 959-972
     CrossRef

103. 103

     Sandeep Ankolekar, Chamila Geeganage, Peter Anderton, Cheryl Hogg, Philip M.W. Bath. (2010) Clinical trials for preventing post stroke cognitive impairment. Journal of the Neurological Sciences 299:1-2, 168-174
     CrossRef

104. 104

     Andrew L Mammen, Anthony A Amato. (2010) Statin myopathy: a review of recent progress. Current Opinion in Rheumatology 22:6, 644-650
     CrossRef

105. 105

     Gregory C. Makris, Anthi Lavida, Andrew N. Nicolaides, George Geroulakos. (2010) The effect of statins on carotid plaque morphology: A LDL-associated action or one more pleiotropic effect of statins?. Atherosclerosis 213:1, 8-20
     CrossRef

106. 106

     Bernard MY Cheung, Karen SL Lam. (2010) Is intensive LDL-cholesterol lowering beneficial and safe?. The Lancet 376:9753, 1622-1624
     CrossRef

107. 107

     P. A. Ringleb, M.-G. Bousser, G. Ford, P. Bath, M. Brainin, V. Caso, Á. Cervera, A.l Chamorro, Charlotte Cordonnier, L. Csiba, A. Davalos, H.-C. Diener, J. Ferro, W. Hacke, M. Hennerici, M. Kaste, P. Langhorne, K. Lees, D. Leys, J. Lodder, H. S. Markus, J.-L. Mas, H. P. Mattle, K. Muir, B. Norrving, V. Obach, S. Paolucci, E. B. Ringelstein, P. D. Schellinger, J. Sivenius, V. Skvortsova, K. Stibrant Sunnerhagen, L. Thomassen, D. Toni, R.r von Kummer, N. Gunnar Wahlgren, M. F. Walker, J. Wardlaw. 2010. Ischaemic Stroke and Transient Ischaemic Attack. , 101-158.
     CrossRef

108. 108

     C.H. Saely, H. Drexel, K. Huber. (2010) Hochdosierte Statintherapie für kardiovaskuläre Risikopatienten. Herz 35:7, 497-502
     CrossRef

109. 109

     Maurizio Paciaroni, Giancarlo Agnelli, Walter Ageno, Valeria Caso, Francesco Corea, Alessia Lanari, Andrea Alberti, Paolo Previdi, Marta Fedele, Giorgia Manina, Cristina Vedovati, Michele Venti, Antonia M.R. Billeci, Maurizio Batta, Luca Galli, Giorgio Silvestrelli. (2010) Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis 212:2, 564-566
     CrossRef

110. 110

     Nils Henninger, Rajat Kumar, Marc Fisher. (2010) Acute ischemic stroke therapy. Expert Review of Cardiovascular Therapy 8:10, 1389-1398
     CrossRef

111. 111

     Ulrich Laufs, Uta C. Hoppe, Stephan Rosenkranz, Paulus Kirchhof, Michael Böhm, Hans-Christoph Diener, Matthias Endres, Martin Grond, Werner Hacke, Thomas Meinertz, E. Bernd Ringelstein, Joachim Röther, Martin Dichgans. (2010) Cardiological evaluation after cerebral ischaemia. Clinical Research in Cardiology 99:10, 609-625
     CrossRef

112. 112

     Kama Z. Guluma, Paul A. Lapchak. (2010) Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke. Brain Research 1354, 206-216
     CrossRef

113. 113

     Dharam J Kumbhani, Deepak L Bhatt. (2010) Secondary prevention of stroke: can we do better than aspirin?. The Lancet Neurology 9:10, 942-943
     CrossRef

114. 114

     Dina Zekry, Gabriel Gold. (2010) Management of Mixed Dementia. Drugs & Aging 27:9, 715-728
     CrossRef

115. 115

     Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, 649-661
     CrossRef

116. 116

     J. David Spence. (2010) Secondary stroke prevention. Nature Reviews Neurology
     CrossRef

117. 117

     Bernadette McGuinness, John O'Hare, David Craig, Roger Bullock, Reem Malouf, Peter Passmore, Bernadette McGuinness. 2010. Statins for the treatment of dementia. .
     CrossRef

118. 118

     Shun Kohsaka, Zhezhen Jin, Tatjana Rundek, Shunichi Homma, Ralph L. Sacco, Marco R. Di Tullio. (2010) Relationship between serum lipid values and atherosclerotic burden in the proximal thoracic aorta. International Journal of Stroke 5:4, 257-263
     CrossRef

119. 119

     Michelle J Porritt, Michelle Chen, Sarah S J Rewell, Rachael G Dean, Louise M Burrell, David W Howells. (2010) ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity. Journal of Cerebral Blood Flow & Metabolism 30:8, 1520-1526
     CrossRef

120. 120

     John R Guyton. (2010) Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology 21:4, 372-377
     CrossRef

121. 121

     Colum F. Amory, Jesse Weinberger. 2010. Cerebrovascular Disease. , 698-709.
     CrossRef

122. 122

     M. Stramba-Badiale. (2010) Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal 31:14, 1677-1681
     CrossRef

123. 123

     Vasilios G Athyros, Konstantinos Tziomalos, Asterios Karagiannis, Anthony S Wierzbicki, Dimitri P Mikhailidis. (2010) Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Current Opinion in Cardiology 25:4, 406-410
     CrossRef

124. 124

     H. F. Lingsma, E. W. Steyerberg, W. J. M. Scholte op Reimer, R. Van Domburg, D. W. J. Dippel, . (2010) Statin treatment after a recent TIA or stroke: is effectiveness shown in randomized clinical trials also observed in everyday clinical practice?. Acta Neurologica Scandinavica 122:1, 15-20
     CrossRef

125. 125

     Jorge Humberto Tapia-Pérez, Martin Sanchez-Aguilar, Thomas Schneider. (2010) The role of statins in neurosurgery. Neurosurgical Review 33:3, 259-270
     CrossRef

126. 126

     Hasan Yilmaz, Vitor Mendes Pereira, Ana-Paula Narata, Roman Sztajzel, Karl-Olof Lovblad. (2010) Carotid artery stenting: Rationale, technique, and current concepts. European Journal of Radiology 75:1, 12-22
     CrossRef

127. 127

     Michael A. Moskowitz, Eng H. Lo, Costantino Iadecola. (2010) The Science of Stroke: Mechanisms in Search of Treatments. Neuron 67:2, 181-198
     CrossRef

128. 128

     David A. Brenner, Rich M. Zweifler, Camilo R. Gomez, Brett M. Kissela, Deborah Levine, George Howard, Bruce Coull, Virginia J. Howard. (2010) Awareness, Treatment, and Control of Vascular Risk Factors among Stroke Survivors. Journal of Stroke and Cerebrovascular Diseases 19:4, 311-320
     CrossRef

129. 129

     Paul A. Lapchak, Moon Ku Han. (2010) Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: Synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. Brain Research 1344, 217-225
     CrossRef

130. 130

     Yoichi Morofuji, Shinsuke Nakagawa, Gohei So, Takeshi Hiu, Shoji Horai, Kentaro Hayashi, Kunihiko Tanaka, Kazuhiko Suyama, Maria A. Deli, Izumi Nagata, Masami Niwa. (2010) Pitavastatin Strengthens the Barrier Integrity in Primary Cultures of Rat Brain Endothelial Cells. Cellular and Molecular Neurobiology 30:5, 727-735
     CrossRef

131. 131

     Graeme J. Hankey, Ka S. L. Wong, Siwaporn Chankrachang, Christopher Chen, Denis Crimmins, Judith Frayne, Jong S. Kim, Yansheng Li, Chia-Wei Liou, Julia S. Merican, Jusuf Misbach, Jose Navarro, Yukito Shinohara, Yongjun Wang, Byung-Woo Yoon. (2010) Management of cholesterol to reduce the burden of stroke in Asia: consensus statement. International Journal of Stroke 5:3, 209-216
     CrossRef

132. 132

     Min Lou, Adnan Safdar, Jonathan A. Edlow, Louis Caplan, Sandeep Kumar, Gottfried Schlaug, D. Eric Searls, Richard P. Goddeau, Magdy Selim. (2010) Can ABCD2 score predict the need for in-hospital intervention in patients with transient ischemic attacks?. International Journal of Emergency Medicine 3:2, 75-80
     CrossRef

133. 133

     N. Butte, B.W. Böttiger, O. Liakopoulos, P. Teschendorf. (2010) Neue Aspekte der perioperativen Statintherapie. Der Anaesthesist 59:6, 539-548
     CrossRef

134. 134

     Natalia S Rost, Jonathan Rosand, Daniel Woo. (2010) Can hyperlipidemia be protective to the brain? The paradox of lowering lipid levels in cerebrovascular disease. Clinical Lipidology 5:3, 295-298
     CrossRef

135. 135

     Eddie Vos. (2010) High-Dose Statin, Not So IDEAL?. Journal of the American College of Cardiology 55:22, 2516-2517
     CrossRef

136. 136

     Yair Lampl, Mordechai Lorberboym, Ronit Gilad, Igor Vysberg, Adele Tikozky, Menachem Sadeh, Mona Boaz. (2010) Early Outcome of Acute Ischemic Stroke in Hyperlipidemic Patients Under Atorvastatin Versus Simvastatin. Clinical Neuropharmacology 33:3, 129-134
     CrossRef

137. 137

     Jorge R. Kizer, Christopher Madias, Brian Wilner, Carl J. Vaughan, Alvin I. Mushlin, Paula Trushin, Antonio M. Gotto, Richard C. Pasternak. (2010) Relation of Different Measures of Low-Density Lipoprotein Cholesterol to Risk of Coronary Artery Disease and Death in a Meta-Regression Analysis of Large-Scale Trials of Statin Therapy. The American Journal of Cardiology 105:9, 1289-1296
     CrossRef

138. 138

     Christopher J. White. (2010) Carotid Artery Stent Placement. JACC: Cardiovascular Interventions 3:5, 467-474
     CrossRef

139. 139

     Kathleen Baldwin, Sean Orr, Mary Briand, Carolyn Piazza, Annita Veydt, Stacey McCoy. (2010) Acute Ischemic Stroke Update. Pharmacotherapy 30:5, 493-514
     CrossRef

140. 140

     Wilbert S. Aronow, William H. Frishman. (2010) Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. Cardiology in Review 18:3, 132-140
     CrossRef

141. 141

     Justine Elliott, Martin Smith. (2010) The Acute Management of Intracerebral Hemorrhage. Anesthesia & Analgesia 110:5, 1419-1427
     CrossRef

142. 142

     U. Laufs, U.C. Hoppe, S. Rosenkranz, P. Kirchhof, M. Böhm, H.-C. Diener, M. Endres, M. Grond, W. Hacke, T. Meinertz, E.B. Ringelstein, J. Röther, M. Dichgans. (2010) Kardiologische Diagnostik nach zerebraler Ischämie. Der Nervenarzt 81:4, 444-462
     CrossRef

143. 143

     Jian-Jun Li, Zong-Liang Lu, Wen-Rong Kou, Zuo Chen, Yang-Feng Wu, Xue-Hai Yu, Yu-Cheng Zhao. (2010) Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). Annals of Medicine 42:3, 231-240
     CrossRef

144. 144

     Antonio Alcalá, Sergio Jansen, Teresa Téllez, Ricardo Gómez-Huelgas, Olga Pérez, Jesús Egido, Michael E. Farkouh. (2010) Statins improve visual field alterations related to hypercholesterolemia. Atherosclerosis 209:2, 510-514
     CrossRef

145. 145

     &NA;. (2010) The Acute (Cerebro) Vascular Effects of Statins. Survey of Anesthesiology 54:2, 100-101
     CrossRef

146. 146

     Francisco M. Gomez-Soto, Sotero P. Romero, Jose A. Bernal, Miguel A. Escobar, Jose L. Puerto, Jose L. Andrey, Pedro Ruiz, Francisco Gomez. (2010) Mortality and morbidity of newly diagnosed heart failure treated with statins. International Journal of Cardiology 140:2, 210-218
     CrossRef

147. 147

     Yiannis S. Chatzizisis, Konstantinos C. Koskinas, Gesthimani Misirli, Christos Vaklavas, Apostolos Hatzitolios, George D. Giannoglou. (2010) Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy. Drug Safety 33:3, 171-187
     CrossRef

148. 148

     Hunter R. Underhill, Thomas S. Hatsukami, Zahi A. Fayad, Valentin Fuster, Chun Yuan. (2010) MRI of carotid atherosclerosis: clinical implications and future directions. Nature Reviews Cardiology 7:3, 165-173
     CrossRef

149. 149

     F. Fluri, F. Hatz, B. Voss, P. A. Lyrer, S. T. Engelter. (2010) Restenosis after carotid endarterectomy: significance of newly acquired risk factors. European Journal of Neurology 17:3, 493-498
     CrossRef

150. 150

     Richard F. Keep, Michael M. Wang, Jianming Xiang, Ya Hua, Guohua Xi. (2010) Is There a Place for Cerebral Preconditioning in the Clinic?. Translational Stroke Research 1:1, 4-18
     CrossRef

151. 151

     Jeffrey M. Gidday. (2010) Pharmacologic Preconditioning: Translating the Promise. Translational Stroke Research 1:1, 19-30
     CrossRef

152. 152

     H. K. Berthold, K. P. Bestehorn, W. Krone, I. Gouni-Berthold. (2010) Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. Diabetic Medicine 27:3, 303-308
     CrossRef

153. 153

     Carl J. Lavie, Richard V. Milani. (2010) High-Dose Atorvastatin in Acute Coronary and Cerebrovascular Syndromes. JACC: Cardiovascular Interventions 3:3, 340-342
     CrossRef

154. 154

     Dexter Y.L. Leung, Felix C.H. Li, Yolanda Y.Y. Kwong, Clement C.Y. Tham, Stanley C.C. Chi, Dennis S.C. Lam. (2010) Simvastatin and Disease Stabilization in Normal Tension Glaucoma: A Cohort Study. Ophthalmology 117:3, 471-476
     CrossRef

155. 155

     M. Gomis, A. Ois, A. Rodríguez-Campello, E. Cuadrado-Godia, J. Jiménez-Conde, I. Subirana, A. Dávalos, J. Roquer. (2010) Outcome of intracerebral haemorrhage patients pre-treated with statins. European Journal of Neurology 17:3, 443-448
     CrossRef

156. 156

     José E. Cohen, John Moshe Gomori, Felix Umansky, Ronen R. Leker. (2010) Therapeutic modalities in symptomatic intracranial arterial occlusive disease. Neurological Research 32:1, 82-86
     CrossRef

157. 157

     Antonio Maiques Galan, Carlos Brotons Cuixart. (2010) Opciones terapéuticas farmacológicas de la dislipemia. Atención Primaria 42:2, 115-120
     CrossRef

158. 158

     Christine Lu-Emerson, David Likosky, Alpesh Amin, David Tirschwell. (2010) Management of ischemic stroke: Part 2. The inpatient stay. Journal of Hospital Medicine 5:2, 88-93
     CrossRef

159. 159

     Hazem F Elewa, Azza B El-Remessy, Payaningal R Somanath, Susan C Fagan. (2010) Diverse Effects of Statins on Angiogenesis: New Therapeutic Avenues. Pharmacotherapy 30:2, 169-176
     CrossRef

160. 160

     Carl J. Pepine. (2010) Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine 42:1, 19-35
     CrossRef

161. 161

     Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Anton JM de Craen, Sreenivasa Rao Kondapally Seshasai, John J McMurray, Dilys J Freeman, J Wouter Jukema, Peter W Macfarlane, Chris J Packard, David J Stott, Rudi G Westendorp, James Shepherd, Barry R Davis, Sara L Pressel, Roberto Marchioli, Rosa Maria Marfisi, Aldo P Maggioni, Luigi Tavazzi, Gianni Tognoni, John Kjekshus, Terje R Pedersen, Thomas J Cook, Antonio M Gotto, Michael B Clearfield, John R Downs, Haruo Nakamura, Yasuo Ohashi, Kyoichi Mizuno, Kausik K Ray, Ian Ford. (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet 375:9716, 735-742
     CrossRef

162. 162

     Elissa F. Wible, Daniel T. Laskowitz. (2010) Statins in traumatic brain injury. Neurotherapeutics 7:1, 62-73
     CrossRef

163. 163

     Noriko Makihara, Yasushi Okada, Masatoshi Koga, Yoshiaki Shiokawa, Jyoji Nakagawara, Eisuke Furui, Kazumi Kimura, Hiroshi Yamagami, Yasuhiro Hasegawa, Kazuomi Kario, Satoshi Okuda, Masaki Naganuma, Kazunori Toyoda. (2010) Effects of statin use on intracranial hemorrhage and clinical outcome after intravenous rt-PA for acute ischemic stroke: SAMURAI rt-PA Registry. Rinsho Shinkeigaku 50:4, 225-231
     CrossRef

164. 164

     Raffaele De Caterina, Marco Scarano, RosaMaria Marfisi, Giuseppe Lucisano, Francesco Palma, Alfonso Tatasciore, Roberto Marchioli. (2010) Cholesterol-Lowering Interventions and Stroke. Journal of the American College of Cardiology 55:3, 198-211
     CrossRef

165. 165

     Yukito Shinohara. (2010) Japanese Guidelines for the Management of Stroke 2009 -Important revised points necessary for the neurologist-. Rinsho Shinkeigaku 50:11, 808-811
     CrossRef

166. 166

     Tomonori Okamura. (2010) Low Blood Chlesterol and Intraparenchymal Hemorrhage in Cohort Studies. Journal of Atherosclerosis and Thrombosis 17:3, 312-314
     CrossRef

167. 167

     R. Eichel, S. T. Khoury, T. Ben-Hur, M. Keidar, R. Paniri, R. R. Leker. (2010) Prior use of statins and outcome in patients with intracerebral haemorrhage. European Journal of Neurology 17:1, 78-83
     CrossRef

168. 168

     O. Hegland, M. W. Kurz, P. S. Munk, J. P. Larsen. (2010) The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity. Acta Neurologica Scandinavica 121:1, 11-15
     CrossRef

169. 169

     Yoichi Ogushi, Yasuo Haruki, Takeo Shibata, Shotai Kobayashi, JSSRS Group. (2010) Hyperlipidemia effects on clinical indexes of stroke in Japanese patients. Nosotchu 32:3, 242-253
     CrossRef

170. 170

     Tomohiro Sakamoto, Hisao Ogawa. (2010) "Just Make It Lower" Is an Alternative Strategy of Lipid-Lowering Therapy With Statins in Japanese Patients. Circulation Journal 74:8, 1731-1741
     CrossRef

171. 171

     B. Bigalke, K. Stellos, T. Geisler, E. Kremmer, P. Seizer, A. E. May, S. Lindemann, A. Melms, A. Luft, M. Gawaz. (2010) Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke. European Journal of Neurology 17:1, 111-117
     CrossRef

172. 172

     Rebecca F. Gottesman, Argye E. Hillis. 2010. Gender Differences in Stroke. , 129-135.
     CrossRef

173. 173

     Andrea Brassard. (2009) Identification of patients at risk of ischemic events for long-term secondary prevention. Journal of the American Academy of Nurse Practitioners 21:12, 677-689
     CrossRef

174. 174

     Adnan I. Qureshi, Edward Feldmann, Camilo R. Gomez, S. Claiborne Johnston, Scott E. Kasner, Donald C. Quick, Peter A. Rasmussen, M. Fareed K. Suri, Robert A. Taylor, Osama O. Zaidat. (2009) Intracranial atherosclerotic disease: An update. Annals of Neurology 66:6, 730-738
     CrossRef

175. 175

     Yannick Béjot, Guy-Victor Osseby, Vincent Gremeaux, Jérôme Durier, Olivier Rouaud, Thibault Moreau, Maurice Giroud. (2009) Changes in risk factors and preventive treatments by stroke subtypes over 20years: A population-based study. Journal of the Neurological Sciences 287:1-2, 84-88
     CrossRef

176. 176

     R. Weber, K. Busch, H.C. Diener. (2009) Schlaganfallsekundärprävention bei Diabetespatienten. Der Diabetologe 5:8, 620-627
     CrossRef

177. 177

     Tomohito Nagaki, Koji Sato, Takaaki Yoshida, Yuhei Yoshimoto. (2009) Benefit of carotid endarterectomy for symptomatic and asymptomatic severe carotid artery stenosis: a Markov model based on data from randomized controlled trials. Journal of Neurosurgery 111:5, 970-977
     CrossRef

178. 178

     Jose Alvarez-Sabin, Manuel Quintana, Miguel Angel Hernandez-Presa, Carlos Alvarez, Jose Chaves, Marc Ribo. (2009) Therapeutic Interventions and Success in Risk Factor Control for Secondary Prevention of Stroke. Journal of Stroke and Cerebrovascular Diseases 18:6, 460-465
     CrossRef

179. 179

     D. Sander, T. Etgen. (2009) Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL. Der Internist 50:11, 1227-1238
     CrossRef

180. 180

     Paul A. Lapchak, Moon Ku Han. (2009) The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Research 1303, 144-150
     CrossRef

181. 181

     Nerses Sanossian, Bruce Ovbiagele. (2009) Prevention and management of stroke in very elderly patients. The Lancet Neurology 8:11, 1031-1041
     CrossRef

182. 182

     Sarah Song, Bruce Ovbiagele. (2009) Management of risk factors for accelerated atherosclerosis. Current Treatment Options in Neurology 11:6, 460-472
     CrossRef

183. 183

     Bernadette McGuinness, Stephen Todd, Peter Passmore, Roger Bullock, Bernadette McGuinness. 2009. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. .
     CrossRef

184. 184

     Philippe Couillard, Alexandre Y Poppe, Shelagh B Coutts. (2009) Predicting recurrent stroke after minor stroke and transient ischemic attack. Expert Review of Cardiovascular Therapy 7:10, 1273-1281
     CrossRef

185. 185

     Maurizio Paciaroni, Julien Bogousslavsky. (2009) Statins and stroke prevention. Expert Review of Cardiovascular Therapy 7:10, 1231-1243
     CrossRef

186. 186

     Dirk Matthias Hermann, Anil Zechariah. (2009) Implications of vascular endothelial growth factor for postischemic neurovascular remodeling. Journal of Cerebral Blood Flow &#38; Metabolism 29:10, 1620-1643
     CrossRef

187. 187

     Shui-ping Zhao, Dao-quan Peng, Bi-lian Yu, Yong Huo. (2009) Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: The CHILLAS study. American Heart Journal 158:4, 509-512.e1
     CrossRef

188. 188

     Dirk Sander, Mark T. Kearney. (2009) Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives. Journal of Neurology 256:10, 1603-1619
     CrossRef

189. 189

     Camilo R. Gomez, Adnan I. Qureshi. (2009) Medical Treatment of Patients with Intracranial Atherosclerotic Disease. Journal of Neuroimaging 19:S1, 25S-29S
     CrossRef

190. 190

     Osama O. Zaidat. (2009) Periprocedural Management of Patients with Endovascular Treatment of Intracranial Atherosclerotic Disease. Journal of Neuroimaging 19:S1, 35S-38S
     CrossRef

191. 191

     David Salat, Roser Ribosa, Lidia Garcia-Bonilla, Joan Montaner. (2009) Statin use before and after acute ischemic stroke onset improves neurological outcome. Expert Review of Cardiovascular Therapy 7:10, 1219-1230
     CrossRef

192. 192

     B. Giannakopoulos, S. A. Krilis. (2009) How I treat the antiphospholipid syndrome. Blood 114:10, 2020-2030
     CrossRef

193. 193

     Niall JJ MacDougall, Sanjay Amarasinghe, Keith W Muir. (2009) Secondary prevention of stroke. Expert Review of Cardiovascular Therapy 7:9, 1103-1115
     CrossRef

194. 194

     Terje R. Pedersen. (2009) Lipid-lowering drugs and risk for cancer. Current Atherosclerosis Reports 11:5, 350-357
     CrossRef

195. 195

     Phayom Sookaneknun, Siritree Suttajit, Chanuttha Ploylearmsang, Juntip Kanjanasilp, Usawadee Maleewong. (2009) Health Promotion Integrated Into a Thai PharmD Curriculum to Improve Pharmacy Practice Skills. American Journal of Pharmaceutical Education 73:5, 78
     CrossRef

196. 196

     Lawrence A. Notaro, Mohammed H. Usman, James F. Burke, Aqeel Siddiqui, Keith R. Superdock, Michael D. Ezekowitz. (2009) Secondary Prevention in Concurrent Coronary Artery, Cerebrovascular, and Chronic Kidney Disease: Focus on Pharmacological Therapy. Cardiovascular Therapeutics 27:3, 199-215
     CrossRef

197. 197

     Thitima Kongnakorn, Alexandra Ward, Craig S. Roberts, Judith A. O'Brien, Irina Proskorovsky, J. Jaime Caro. (2009) Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial. Value in Health 12:6, 880-887
     CrossRef

198. 198

     Nagaendran Kandiah, Howard H. Feldman. (2009) Therapeutic potential of statins in Alzheimer's disease. Journal of the Neurological Sciences 283:1-2, 230-234
     CrossRef

199. 199

     Lonneke ML de Lau, Heleen M den Hertog, Evita G van den Herik, Peter J Koudstaal. (2009) Predicting and preventing stroke after transient ischemic attack. Expert Review of Neurotherapeutics 9:8, 1159-1170
     CrossRef

200. 200

     Naoki Sawada, James K Liao. (2009) Targeting eNOS and beyond: emerging heterogeneity of the role of endothelial Rho proteins in stroke protection. Expert Review of Neurotherapeutics 9:8, 1171-1186
     CrossRef

201. 201

     G. Melissano, R. Chiesa. (2009) The “Other Revolution” in Stroke Prevention. European Journal of Vascular and Endovascular Surgery 38:2, 141-142
     CrossRef

202. 202

     Vincent Prinz, Matthias Endres. (2009) The Acute (Cerebro)Vascular Effects of Statins. Anesthesia & Analgesia 109:2, 572-584
     CrossRef

203. 203

     Bradley N Manktelow, John F Potter, Bradley N Manktelow. 2009. Interventions in the management of serum lipids for preventing stroke recurrence. .
     CrossRef

204. 204

     Morteza Enajat, Steven Teerenstra, Janet T. van Kuilenburg, Aty H.N. van Sorge-Greve, Marjo T.H. Albers-Akkers, Freek W.A. Verheugt, Gheorghe A.M. Pop. (2009) Safety of the Combination of Intensive Cholesterol-Lowering Therapy with Oral Anticoagulation Medication in Elderly Patients with Atrial Fibrillation. Drugs & Aging 26:7, 585-593
     CrossRef

205. 205

     Kenneth M. Welch. (2009) Review of the SPARCL trial and its subanalyses. Current Atherosclerosis Reports 11:4, 315-321
     CrossRef

206. 206

     Apostolos I. Hatzitolios, Triandafillos P. Didangelos, Anestis T. Zantidis, Konstantinos Tziomalos, George A. Giannakoulas, Dimitrios T. Karamitsos. (2009) Diabetes mellitus and cerebrovascular disease: which are the actual data?. Journal of Diabetes and its Complications 23:4, 283-296
     CrossRef

207. 207

     Marcella A Evans, Beatrice A Golomb. (2009) Statin-Associated Adverse Cognitive Effects: Survey Results from 171 Patients. Pharmacotherapy 29:7, 800-811
     CrossRef

208. 208

     Stephen D. Wiviott, Satishkumar Mohanavelu, Joel S. Raichlen, Valerie A. Cain, Steven E. Nissen, Peter Libby. (2009) Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study). The American Journal of Cardiology 104:1, 29-35
     CrossRef

209. 209

     Henrik Sillesen. (2009) Statins and their use in preventing carotid disease. Current Atherosclerosis Reports 11:4, 309-314
     CrossRef

210. 210

     H.-C. Diener, C. Weimar. (2009) Update of secondary stroke prevention. Nephrology Dialysis Transplantation 24:6, 1718-1724
     CrossRef

211. 211

     Larry B. Goldstein. (2009) New data about stenting versus endarterectomy for symptomatic carotid artery stenosis. Current Treatment Options in Cardiovascular Medicine 11:3, 232-240
     CrossRef

212. 212

     G. Schernthaner. (2009) Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors. International Journal of Clinical Practice 63:6, 912-929
     CrossRef

213. 213

     Pierre Amarenco, Larry B. Goldstein, Alfred Callahan, Henrik Sillesen, Michael G. Hennerici, Blair J. O’Neill, Amy E. Rudolph, Lisa Simunovic, Justin A. Zivin, K.M.A. Welch. (2009) Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 204:2, 515-520
     CrossRef

214. 214

     Pierre Amarenco, Julien Labreuche. (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. The Lancet Neurology 8:5, 453-463
     CrossRef

215. 215

     Vincent C. T. Mok, Wynnie W. M. Lam, Yu Hua Fan, Adrian Wong, Ping Wing Ng, Tak Hon Tsoi, Vincent Yeung, Ka Sing Wong. (2009) Effects of statins on the progression of cerebral white matter lesion. Journal of Neurology 256:5, 750-757
     CrossRef

216. 216

     William Clifford Roberts. (2009) Evaluating Lipid-Lowering Trials in the Twenty-First Century. The American Journal of Cardiology 103:9, 1325-1328
     CrossRef

217. 217

     María G. Barderas, José Tuñón, Verónica M. Dardé, Fernando De la Cuesta, José J. Jiménez-Nácher, Nieves Tarín, Lorenzo López-Bescós, Jesús Egido, Fernando Vivanco. (2009) Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome. PROTEOMICS 9:7, 1982-1993
     CrossRef

218. 218

     Julien Labreuche, Pierre-Jean Touboul, Pierre Amarenco. (2009) Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: A systematic review of the epidemiological studies. Atherosclerosis 203:2, 331-345
     CrossRef

219. 219

     Howard S. Kirshner. (2009) Differentiating ischemic stroke subtypes: Risk factors and secondary prevention. Journal of the Neurological Sciences 279:1-2, 1-8
     CrossRef

220. 220

     Wilbert S. Aronow. (2009) Acute and Chronic Management of Atrial Fibrillation in Patients With Late-Stage CKD. American Journal of Kidney Diseases 53:4, 701-710
     CrossRef

221. 221

     Giuseppe Lanzino, Alejandro A. Rabinstein, Robert D. Brown. (2009) Treatment of Carotid Artery Stenosis: Medical Therapy, Surgery, or Stenting?. Mayo Clinic Proceedings 84:4, 362-368
     CrossRef

222. 222

     G. Lanzino, A. A. Rabinstein, R. D. Brown. (2009) Treatment of Carotid Artery Stenosis: Medical Therapy, Surgery, or Stenting?. Mayo Clinic Proceedings 84:4, 362-368
     CrossRef

223. 223

     Cara Camiolo Reddy, Alex Moroz, Steven R. Edgley, Henry L. Lew, John Chae, Lisa A. Lombard. (2009) Stroke and Neurodegenerative Disorders: 1. Stroke Management in the Acute Care Setting. PM&R 1:3, S4-S12
     CrossRef

224. 224

     Latha G. Stead, Lekshmi Vaidyanathan, Gautam Kumar, M. Fernanda Bellolio, Robert D. Brown, Smitha Suravaram, Sailaja Enduri, Rachel M. Gilmore, Wyatt W. Decker. (2009) Statins in Ischemic Stroke: Just Low-Density Lipoprotein Lowering or More?. Journal of Stroke and Cerebrovascular Diseases 18:2, 124-127
     CrossRef

225. 225

     John Protopsaltis, Stelios Kokkoris, Panagiotis Korantzopoulos, Haralampos J. Milionis, Efthalia Karzi, Alexandra Anastasopoulou, Kostantina Filioti, Stavros Antonopoulos, Andreas Melidonis, Grigorios Giannoulis. (2009) Prediction of long-term functional outcome in patients with acute ischemic non-embolic stroke. Atherosclerosis 203:1, 228-235
     CrossRef

226. 226

     Chiaki Yokota, Kazuo Minematsu, Atsushi Ito, Kazunori Toyoda, Hikaru Nagasawa, Takenori Yamaguchi. (2009) Albuminuria, but not metabolic syndrome, is a significant predictor of stroke recurrence in ischemic stroke. Journal of the Neurological Sciences 277:1-2, 50-53
     CrossRef

227. 227

     Steven M Greenberg, Meike W Vernooij, Charlotte Cordonnier, Anand Viswanathan, Rustam Al-Shahi Salman, Steven Warach, Lenore J Launer, Mark A Van Buchem, Monique MB Breteler. (2009) Cerebral microbleeds: a guide to detection and interpretation. The Lancet Neurology 8:2, 165-174
     CrossRef

228. 228

     Michael Ross, Fadi Nahab. (2009) Management of Transient Ischemia Attacks in the Twenty-First Century. Emergency Medicine Clinics of North America 27:1, 51-69
     CrossRef

229. 229

     Philippa J. Delahoy, Dianna J. Magliano, Kate Webb, Mendel Grobler, Danny Liew. (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics 31:2, 236-244
     CrossRef

230. 230

     Mary Jo V. Pugh, Janice E. Knoefel, Eric M. Mortensen, Megan E. Amuan, Dan R. Berlowitz, Anne C. Van Cott. (2009) New-Onset Epilepsy Risk Factors in Older Veterans. Journal of the American Geriatrics Society 57:2, 237-242
     CrossRef

231. 231

     V. Charlton-Menys, D. J. Betteridge, H. Colhoun, J. Fuller, M. France, G. A. Hitman, S. J. Livingstone, H. A. W. Neil, C. B. Newman, M. Szarek, D. A. DeMicco, P. N. Durrington. (2009) Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 52:2, 218-225
     CrossRef

232. 232

     Matthew F Giles, Peter M Rothwell. (2009) Transient ischaemic attack: clinical relevance, risk prediction and urgency of secondary prevention. Current Opinion in Neurology 22:1, 46-53
     CrossRef

233. 233

     Alberico L. Catapano. (2009) Perspectives on low-density lipoprotein cholesterol goal achievement. Current Medical Research and Opinion 25:2, 431-447
     CrossRef

234. 234

     I. Holme, A. H. Aastveit, N. Hammar, I. Jungner, G. Walldius. (2009) Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). Journal of Internal Medicine 265:2, 275-287
     CrossRef

235. 235

     J. Castillo, J. Álvarez-Sabín, E. Martínez-Vila, J. Montaner, T. Sobrino, J. Vivancos, . (2009) Inflammation markers and prediction of post-stroke vascular disease recurrence: The MITICO study. Journal of Neurology 256:2, 217-224
     CrossRef

236. 236

     Bernadette McGuinness, Roger Bullock, David Craig, Enda Kerr, Peter Passmore, Bernadette McGuinness. 2009. Statins for the treatment of Alzheimer's disease and dementia. .
     CrossRef

237. 237

     Alessandro Squizzato, Erica Romualdi, Francesco Dentali, Walter Ageno, Alessandro Squizzato. 2009. Statins for acute ischemic stroke. .
     CrossRef

238. 238

     Jennifer G. Robinson, Songfeng Wang, Brian J. Smith, Terry A. Jacobson. (2009) Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. Journal of the American College of Cardiology 53:4, 316-322
     CrossRef

239. 239

     Sadollah Abedini, Ingar Holme, Bengt Fellström, Alan Jardine, Edward Cole, Bart Maes, Hallvard Holdaas. (2009) Cerebrovascular Events in Renal Transplant Recipients. Transplantation 87:1, 112-117
     CrossRef

240. 240

     Carol M. Mason. (2009) Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model. Journal of the American Academy of Nurse Practitioners 21:1, 47-53
     CrossRef

241. 241

     Christos Vaklavas, Yiannis S. Chatzizisis, Anthony Ziakas, Chrysanthos Zamboulis, George D. Giannoglou. (2009) Molecular basis of statin-associated myopathy. Atherosclerosis 202:1, 18-28
     CrossRef

242. 242

     P.R. Gajendragadkar, D.G. Cooper, S.R. Walsh, T.Y. Tang, J.R. Boyle, P.D. Hayes. (2009) Novel uses for statins in surgical patients. International Journal of Surgery 7:4, 285-290
     CrossRef

243. 243

     Jens Minnerup, Wolf-Rüdiger Schäbitz. (2009) Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 6:1, 43-52
     CrossRef

244. 244

     Tomohito Hamazaki. (2009) Are the upper limits for serum cholesterol levels necessary?. Journal of Lipid Nutrition 18:1, 33-50
     CrossRef

245. 245

     Kazunori Toyoda. (2009) Pharmacotherapy for the Secondary Prevention of Stroke. Drugs 69:6, 633-647
     CrossRef

246. 246

     P. Martínez-Sánchez, C. Rivera-Ordóñez, B. Fuentes, M. A. Ortega-Casarrubios, L. Idrovo, E. Díez-Tejedor. (2009) The beneficial effect of statins treatment by stroke subtype. European Journal of Neurology 16:1, 127-133
     CrossRef

247. 247

     Cheryl D. Bushnell, Cathleen S. Colón-Emeric. (2009) Secondary Stroke Prevention Strategies for the Oldest Patients. Drugs & Aging 26:3, 209-230
     CrossRef

248. 248

     Anton F.H. Stalenhoef. (2009) The benefit of statins in non-cardiac vascular surgery patients. Journal of Vascular Surgery 49:1, 260-265
     CrossRef

249. 249

     Babak B. Navi, Alan Z. Segal. (2009) The role of cholesterol and statins in stroke. Current Cardiology Reports 11:1, 4-11
     CrossRef

250. 250

     H. P. Adams. (2009) Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clinic Proceedings 84:1, 43-51
     CrossRef

251. 251

     Adrienne Keener, Nerses Sanossian. (2008) Niacin for Stroke Prevention: Evidence and Rationale. CNS Neuroscience & Therapeutics 14:4, 287-294
     CrossRef

252. 252

     Jocelyne G. Karam, Lisel Loney-Hutchinson, Samy I. McFarlane. (2008) High-Dose Atorvastatin After Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Journal of the CardioMetabolic Syndrome 3:1, 68-69
     CrossRef

253. 253

     William Virgil Brown. (2008) Safety of statins. Current Opinion in Lipidology 19:6, 558-562
     CrossRef

254. 254

     Seung-Hoon Lee, Yoon-Hee Kim, Young-Ju Kim, Byung-Woo Yoon. (2008) Atorvastatin enhances hypothermia-induced neuroprotection after stroke. Journal of the Neurological Sciences 275:1-2, 64-68
     CrossRef

255. 255

     M.W. Merx, C. Weber. (2008) Benefits of statins beyond lipid lowering. Drug Discovery Today: Disease Mechanisms 5:3-4, e325-e331
     CrossRef

256. 256

     Ridker, Paul M, Danielson, Eleanor, Fonseca, Francisco A.H., Genest, Jacques, Gotto, Antonio M. Jr., Kastelein, John J.P., Koenig, Wolfgang, Libby, Peter, Lorenzatti, Alberto J., MacFadyen, Jean G., Nordestgaard, Børge G., Shepherd, James, Willerson, James T., Glynn, Robert J., . (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine 359:21, 2195-2207
     Full Text

257. 257

     Tatjana Rundek, Ralph L. Sacco. (2008) Risk Factor Management to Prevent First Stroke. Neurologic Clinics 26:4, 1007-1045
     CrossRef

258. 258

     Francisco José Fernández Fernández, Tamara Caínzos Romero, Gonzalo Pía Iglesias, Pascual Sesma. (2008) Estatinas y accidente cerebrovascular. Medicina Clínica 131:14, 559
     CrossRef

259. 259

     Mathew J Reeves, Cheryl D Bushnell, George Howard, Julia Warner Gargano, Pamela W Duncan, Gwen Lynch, Arya Khatiwoda, Lynda Lisabeth. (2008) Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. The Lancet Neurology 7:10, 915-926
     CrossRef

260. 260

     P.D. Schellinger, P. Ringleb, W. Hacke. (2008) Leitlinien zum Management von Patienten mit akutem Hirninfarkt oder TIA der Europäischen Schlaganfallorganisation 2008. Der Nervenarzt 79:10, 1180-1202
     CrossRef

261. 261

     Gregory P Van Stavern, Renee B Van Stavern. (2008) Stroke and visual loss. Expert Review of Ophthalmology 3:5, 529-541
     CrossRef

262. 262

     George Bakris, Michael Böhm, Gilles Dagenais, Hans-Christoph Diener, Toshiro Fujita, Philip Gorelick, Sverre Erik Kjeldsen, Markku Laakso, Giuseppe Mancia, Bertram Pitt, Arya Sharma, Peter Sleight, Koon Teo, Thomas Unger, Michael Weber, Bryan Williams, Faiez Zannad. (2008) Cardiovascular protection for all individuals at high risk: evidence-based best practice. Clinical Research in Cardiology 97:10, 713-725
     CrossRef

263. 263

     John C. LaRosa, Scott M. Grundy, David D. Waters. 2008. TNT Trial. .
     CrossRef

264. 264

     Emile Mohler, Jay Giri. (2008) Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Current Medical Research and Opinion 24:9, 2509-2522
     CrossRef

265. 265

     David H. Fitchett, Shaun G. Goodman, Anatoly Langer. (2008) Ischemic stroke: A cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Canadian Journal of Cardiology 24:9, 705-708
     CrossRef

266. 266

     A. Torres do Rego, L.A. Álvarez-Sala Walter, P. Conthe Gutiérrez. (2008) Lípidos y enfermedad cerebrovascular. El papel de las estatinas. Nuevas opciones hipolipemiantes en investigación. Revista Clínica Española 208, 13-18
     CrossRef

267. 267

     Geoffrey A Donnan, Marc Fisher, Malcolm Macleod, Stephen M Davis. (2008) Secondary prevention of stroke – Authors' reply. The Lancet 372:9643, 1036
     CrossRef

268. 268

     José Biller. (2008) The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice. Neurological Research 30:7, 669-677
     CrossRef

269. 269

     Luca Mascitelli, Francesca Pezzetta, Mark R Goldstein. (2008) Secondary prevention of stroke. The Lancet 372:9643, 1035
     CrossRef

270. 270

     Mahmut Edip Gurol, Steven M. Greenberg. (2008) Management of intracerebral hemorrhage. Current Atherosclerosis Reports 10:4, 324-331
     CrossRef

271. 271

     J. Humberto Tapia-Perez, Martin Sanchez-Aguilar, Jaime Gerardo Torres-Corzo, Antonio Gordillo-Moscoso, Patricia Martinez-Perez, Peter Madeville, Esperanza de la Cruz-Mendoza, Juan Chalita-Williams. (2008) Effect of Rosuvastatin on Amnesia and Disorientation after Traumatic Brain Injury (NCT003229758). Journal of Neurotrauma 25:8, 1011-1017
     CrossRef

272. 272

     Nerses Sanossian, Bruce Ovbiagele. (2008) The risk of stroke within a week of minor stroke or transient ischemic attack. Expert Opinion on Pharmacotherapy 9:12, 2069-2076
     CrossRef

273. 273

     Samir H. Shah, Rita Engelhardt, Bruce Ovbiagele. (2008) Patterns of complementary and alternative medicine use among United States stroke survivors. Journal of the Neurological Sciences 271:1-2, 180-185
     CrossRef

274. 274

     Brett Cucchiara, Michael Ross. (2008) Transient Ischemic Attack: Risk Stratification and Treatment. Annals of Emergency Medicine 52:2, S27-S39
     CrossRef

275. 275

     Ana-Maria Simundic, Nora Nikolac, Elizabeta Topic, Vanja Basic-Kes, Vida Demarin. (2008) Are serum lipids measured on stroke admission prognostic?. Clinical Chemistry and Laboratory Medicine 46:8, 1163-1167
     CrossRef

276. 276

     James H. O'Keefe, Kevin A. Bybee, Carl J. Lavie. (2008) Intensive Lipid Intervention in the Post-ENHANCE Era. Mayo Clinic Proceedings 83:8, 867-869
     CrossRef

277. 277

     J. H. O'Keefe, K. A. Bybee, C. J. Lavie. (2008) Intensive Lipid Intervention in the Post-ENHANCE Era. Mayo Clinic Proceedings 83:8, 867-869
     CrossRef

278. 278

     Hyung-Hwan Kim, Naoki Sawada, Guray Soydan, Ho-Seong Lee, Zhipeng Zhou, Seo-Kyoung Hwang, Christian Waeber, Michael A Moskowitz, James K Liao. (2008) Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. Journal of Cerebral Blood Flow &#38; Metabolism 28:7, 1285-1293
     CrossRef

279. 279

     William H. Frishman, John Horn. (2008) Statin???Drug Interactions. Cardiology in Review 16:4, 205-212
     CrossRef

280. 280

     C. Sanclemente Ansó, A. Pedragosa Vall, E. Rovira Pujol, D. Vigil Martín. (2008) El ictus en manos del internista. Factores de riesgo cardiovascular. Revista Clínica Española 208:7, 339-346
     CrossRef

281. 281

     Almudena Gómez-Hernández, Eva Sánchez-Galán, Mónica Ortego, José Luis Martín-Ventura, Luis Miguel Blanco-Colio, Nieves Tarín-Vicente, José Julio Jiménez-Nacher, Lorenzo López-Bescos, Jesús Egido, José Tuñón. (2008) Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome. The American Journal of Cardiology 102:1, 12-18
     CrossRef

282. 282

     Larry B. Goldstein. (2008) 10 Questions About Statins and Stroke. The Neurologist 14:4, 262-264
     CrossRef

283. 283

     Tinetti, Mary E., . (2008) Over-the-Counter Sales of Statins and Other Drugs for Asymptomatic Conditions. New England Journal of Medicine 358:25, 2728-2732
     Full Text

284. 284

     P. Amarenco, P. G. Steg. (2008) Stroke is a coronary heart disease risk equivalent: implications for future clinical trials in secondary stroke prevention. European Heart Journal 29:13, 1605-1607
     CrossRef

285. 285

     Pablo del Saz-Saucedo, José Francisco Maestre-Moreno, Juan Francisco Arenillas-Lara. (2008) Ateromatosis intracraneal. Medicina Clínica 131:4, 141-152
     CrossRef

286. 286

     Pierre Amarenco, Philippa C Lavallée, Mikael Mazighi, Julien Labreuche. (2008) Statins in stroke prevention. Future Lipidology 3:3, 319-325
     CrossRef

287. 287

     M. Uyttenboogaart, M. W. Koch, K. Koopman, P. C. Vroomen, G. J. Luijckx, J. Keyser. (2008) Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke. Journal of Neurology 255:6, 875-880
     CrossRef

288. 288

     Yuka Terasawa, Yasuyuki Iguchi, Kazumi Kimura, Kazuto Kobayashi, Junya Aoki, Noriko Matsumoto, Kensaku Shibazaki, Takeshi Inoue, Ryuji Kaji. (2008) Neurological deterioration in small vessel disease may be associated with increase of infarct volume. Journal of the Neurological Sciences 269:1-2, 35-40
     CrossRef

289. 289

     Nerses Sanossian, Nicholas E. Tarlov. (2008) HDL-C and LDL-C: Their role in stroke pathogenesis and implications for treatment. Current Treatment Options in Cardiovascular Medicine 10:3, 195-206
     CrossRef

290. 290

     Janja Pretnar-Oblak, Miran Sebestjen, Miso Sabovic. (2008) Statin Treatment Improves Cerebral More Than Systemic Endothelial Dysfunction in Patients With Arterial Hypertension. American Journal of Hypertension 21:6, 674-678
     CrossRef

291. 291

     Lynn M. Fedoruk, Hongkun Wang, Mark R. Conaway, Irving L. Kron, Karen C. Johnston. (2008) Statin Therapy Improves Outcomes After Valvular Heart Surgery. The Annals of Thoracic Surgery 85:5, 1521-1526
     CrossRef

292. 292

     Tomás Segura, Sergio Calleja, Joaquin Jordan. (2008) Recommendations and treatment strategies for the management of acute ischemic stroke. Expert Opinion on Pharmacotherapy 9:7, 1071-1085
     CrossRef

293. 293

     Amy E Miller, Laura B Hansen, Joseph J Saseen. (2008) Switching Statin Therapy Using a Pharmacist-Managed Therapeutic Conversion Program versus Usual Care Conversion Among Indigent Patients. Pharmacotherapy 28:5, 553-561
     CrossRef

294. 294

     JB Warren. (2008) Cholesterol—When Is Lower Better?. Clinical Pharmacology &#38; Therapeutics 83:5, 777-780
     CrossRef

295. 295

     Geoffrey A Donnan, Marc Fisher, Malcolm Macleod, Stephen M Davis. (2008) Stroke. The Lancet 371:9624, 1612-1623
     CrossRef

296. 296

     Kelvin Hill. (2008) Australian Clinical Guidelines for Acute Stroke Management 2007.. International Journal of Stroke 3:2, 120-129
     CrossRef

297. 297

     Sanjiv J. Shah, David D. Waters, Philip Barter, John J.P. Kastelein, James Shepherd, Nanette K. Wenger, David A. DeMicco, Andrei Breazna, John C. LaRosa. (2008) Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 51:20, 1938-1943
     CrossRef

298. 298

     Manuel Rodríguez-Yáñez, Antonio Dávalos, José Castillo. (2008) Withdrawal from statins: implications for secondary stroke prevention and acute treatment. International Journal of Stroke 3:2, 85-87
     CrossRef

299. 299

     D Benson Walker, Terry A Jacobson. (2008) Initiating statins in the elderly: the evolving challenge. Current Opinion in Endocrinology, Diabetes and Obesity 15:2, 182-187
     CrossRef

300. 300

     Manuel Rodríguez Yañez, Antoni Dávalos. (2008) Estatinas y accidente cerebrovascular. Medicina Clínica 130:12, 453-454
     CrossRef

301. 301

     HT Ong, AG Haniffah. (2008) Cholesterol, statins, and mortality. The Lancet 371:9619, 1161
     CrossRef

302. 302

     Kevin A. Bybee, John H. Lee, James H. O'Keefe. (2008) Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current Medical Research and Opinion 24:4, 1217-1229
     CrossRef

303. 303

     Jose G. Romano, Ralph L. Sacco. (2008) Progress in secondary stroke prevention. Annals of Neurology 63:4, 418-427
     CrossRef

304. 304

     Jean-Marc Bugnicourt, Jean-Marc Chillon, Sandrine Canaple, Chantal Lamy, Olivier Godefroy. (2008) Stroke secondary prevention and blood pressure reduction: an observational study of the use of PROGRESS therapy. Fundamental & Clinical Pharmacology 22:2, 217-222
     CrossRef

305. 305

     J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:2, 115-125
     CrossRef

306. 306

     María Grau, Jaume Marrugat. (2008) Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Revista Española de Cardiología 61:4, 404-416
     CrossRef

307. 307

     Kumar Rajamani, Seemant Chaturvedi. (2008) New strategies in the medical treatment of carotid artery disease. Current Treatment Options in Cardiovascular Medicine 10:2, 156-163
     CrossRef

308. 308

     Herman Vandenburgh, Janet Shansky, Frank Benesch-Lee, Victoria Barbata, Jonathan Reid, Lieven Thorrez, Robert Valentini, Gregory Crawford. (2008) Drug-screening platform based on the contractility of tissue-engineered muscle. Muscle & Nerve 37:4, 438-447
     CrossRef

309. 309

     Sarah Lewington, Gary Whitlock, Robert Clarke, Paul Sherliker, Jonathan Emberson, Rory Collins. (2008) Cholesterol, statins, and mortality – Authors' reply. The Lancet 371:9619, 1162-1163
     CrossRef

310. 310

     Jeffrey L. Cummings. (2008) Progress in Neurotherapeutics and Neuropsychopharmacology 2008. Progress in Neurotherapeutics and Neuropsychopharmacology 3:01,
     CrossRef

311. 311

     Elad I. Levy, J. Mocco, Rodney M. Samuelson, Robert D. Ecker, Babak S. Jahromi, L. Nelson Hopkins. (2008) Optimal Treatment of Carotid Artery Disease. Journal of the American College of Cardiology 51:10, 979-985
     CrossRef

312. 312

     Soon-Tae Lee, Kon Chu, Jung-Eun Park, Nan Hyung Hong, Woo-Seok Im, Lami Kang, Zhe Han, Keun-Hwa Jung, Min-Wook Kim, Manho Kim. (2008) Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways. Journal of Neurochemistry 104:5, 1190-1200
     CrossRef

313. 313

     Roy W. Jones, Miia Kivipelto, Howard Feldman, Larry Sparks, Rachelle Doody, David D. Waters, Judith Hey-Hadavi, Andrei Breazna, Rachel J. Schindler, Harry Ramos. (2008) The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): Design and baseline characteristicsRoy W. Jones and Miia Kivipelto contributed equally to the content of the manuscript.. Alzheimer's and Dementia 4:2, 145-153
     CrossRef

314. 314

     Paige Moorhouse, Kenneth Rockwood. (2008) Vascular cognitive impairment: current concepts and clinical developments. The Lancet Neurology 7:3, 246-255
     CrossRef

315. 315

     Hagen Kunte, Nicola Amberger, Markus Alexander Busch, Ralph-Ingo Rückert, Silke Meiners, Lutz Harms. (2008) Markers of instability in high-risk carotid plaques are reduced by statins. Journal of Vascular Surgery 47:3, 513-522
     CrossRef

316. 316

     Shelagh B. Coutts, Michael Eliasziw, Michael D. Hill, James N. Scott, Suresh Subramaniam, Alastair M. Buchan, Andrew M. Demchuk, . (2008) An improved scoring system for identifying patients at high early risk of stroke and functional impairment after an acute transient ischemic attack or minor stroke. International Journal of Stroke 3:1, 3-10
     CrossRef

317. 317

     Jesse Weinberger. 2008. Cerebrovascular Disease in the Elderly Patient. , 645-672.
     CrossRef

318. 318

     Joseph E. Thomas, JoAnne M. Foody. 2008. Disorders of Lipid Metabolism. , 159-178.
     CrossRef

319. 319

     Pierre Amarenco, Julien Labreuche, Pierre-Jean Touboul. (2008) High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: A systematic review. Atherosclerosis 196:2, 489-496
     CrossRef

320. 320

     Neeraj S. Naval, Tamer A. Abdelhak, Paloma Zeballos, Nathalie Urrunaga, Marek A. Mirski, Juan R. Carhuapoma. (2008) Prior Statin Use Reduces Mortality in Intracerebral Hemorrhage. Neurocritical Care 8:1, 6-12
     CrossRef

321. 321

     Susan C. Fagan. (2008) Urgent Need for Secondary Stroke Prevention After Transient Ischemic Attack. The Consultant Pharmacist 23:2, 131-140
     CrossRef

322. 322

     J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:1, 31-41
     CrossRef

323. 323

     Masaji Murakami, Shodo Fujioka, Yoshifumi Hirata, Jun-ichi Kuratsu. (2008) Low-dose of Statin Treatment Improves Cerebrovascular Reactivity in Patients With Ischemic Stroke: Single Photon Emission Computed Tomography Analysis. Journal of Stroke and Cerebrovascular Diseases 17:1, 16-22
     CrossRef

324. 324

     (2008) Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008. Cerebrovascular Diseases 25:5, 457-507
     CrossRef

325. 325

     Tamio Teramoto, Jun Sasaki, Hirotsugu Ueshima, Genshi Egusa, Makoto Kinoshita, Kazuaki Shimamoto, Hiroyuki Daida, Sadatoshi Biro, Kazuhiko Hirobe, Tohru Funahashi, Koutaro Yokote, Masayuki Yokode. (2008) Treatment - Drug Therapy. Journal of Atherosclerosis and Thrombosis 15:4, 167-178
     CrossRef

326. 326

     James K Liao. (2008) Is statin discontinuation an option in patients who have had a stroke?. Nature Clinical Practice Neurology 4:1, 18-19
     CrossRef

327. 327

     William E. Braun. 2008. Cardiovascular and Other Noninfectious Complications after Renal Transplantation in Adults. , 1009-1033.
     CrossRef

328. 328

     Robert A. Phillips. (2008) A Review of Therapeutic Strategies for Risk Reduction of Recurrent Stroke. Progress in Cardiovascular Diseases 50:4, 264-273
     CrossRef

329. 329

     Joachim R&ouml;ther, Mark J. Alberts, Emmanuel Touz&eacute;, Jean-Louis Mas, Michael D. Hill, Patrik Michel, Deepak L. Bhatt, Franz T. Aichner, Shinya Goto, Masayasu Matsumoto, E. Magnus Ohman, Yasushi Okada, Shinichiro Uchiyama, Ralph D&rsquo;Agostino, Alan T. Hirsch, Peter W.F. Wilson, P. Gabriel Steg. (2008) Risk Factor Profile and Management of Cerebrovascular Patients in the REACH Registry. Cerebrovascular Diseases 25:4, 366-374
     CrossRef

330. 330

     Christopher O’Regan, Ping Wu, Paul Arora, Dan Perri, Edward J. Mills. (2008) Statin Therapy in Stroke Prevention: A Meta-analysis Involving 121,000 Patients. The American Journal of Medicine 121:1, 24-33
     CrossRef

331. 331

     G.L. Moneta. (2008) High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. Yearbook of Vascular Surgery 2008, 262-264
     CrossRef

332. 332

     Woo-Keun Seo, Hwan S. Yong, Seong-Beom Koh, Sang-il Suh, Ji H. Kim, Sung-Wook Yu, Ji-Yeon Lee. (2008) Correlation of Coronary Artery Atherosclerosis with Atherosclerosis of the Intracranial Cerebral Artery and the Extracranial Carotid Artery. European Neurology 59:6, 292-298
     CrossRef

333. 333

     Daisuke Uematsu. (2008) New assessment for the risk of ischemic stroke or carotid artery stenosis: Prognostic factor analysis in hypercholesterolemia patients. Nosotchu 30:4, 562-569
     CrossRef

334. 334

     Matthias W Riepe, Roman Huber. (2008) Secondary Stroke Prevention. CNS Drugs 22:2, 113-121
     CrossRef

335. 335

     J. David Orr. (2008) Statins in the spectrum of neurologic disease. Current Atherosclerosis Reports 10:1, 11-18
     CrossRef

336. 336

     Nerses Sanossian, Bruce Ovbiagele. (2008) Drug Insight: translating evidence on statin therapy into clinical benefits. Nature Clinical Practice Neurology 4:1, 43-49
     CrossRef

337. 337

     Mikael Mazighi, Philippa C Lavallée, Julien Labreuche, Pierre Amarenco. (2007) Statin therapy and stroke prevention: what was known, what is new and what is next?. Current Opinion in Lipidology 18:6, 622-625
     CrossRef

338. 338

     Pierre Amarenco, P Gabriel Steg. (2007) The paradox of cholesterol and stroke. The Lancet 370:9602, 1803-1804
     CrossRef

339. 339

     Annemarie Armani, Peter P. Toth. (2007) SPARCL: The glimmer of statins for stroke risk reduction. Current Atherosclerosis Reports 9:5, 347-351
     CrossRef

340. 340

     James Kennedy, Michael D Hill, Karla J Ryckborst, Michael Eliasziw, Andrew M Demchuk, Alastair M Buchan. (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. The Lancet Neurology 6:11, 961-969
     CrossRef

341. 341

     S Claiborne Johnston. (2007) Towards FASTER treatment of TIA and minor stroke. The Lancet Neurology 6:11, 941-943
     CrossRef

342. 342

     E. Durán Ferreras, J. Viguera Romero, C. Martínez Parra. (2007) Accidente isquémico transitorio. Revista Clínica Española 207:10, 505-507
     CrossRef

343. 343

     Jeffrey A. Switzer, David C. Hess. (2007) Carotid stenosis: Endarterectomy or angioplasty and stenting?. Current Treatment Options in Neurology 9:6, 451-462
     CrossRef

344. 344

     Teng-Yeow Tan, Ku-Chou Chang, Ulf Schminke, Tsung-Kung Lin, Yu-Ching Huang, Jen-Wen Hung, Ting-Yao Chen. (2007) Lipid management in ischemic stroke patients. Clinical Neurology and Neurosurgery 109:9, 758-762
     CrossRef

345. 345

     Pierre Amarenco. (2007) Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opinion on Pharmacotherapy 8:16, 2789-2797
     CrossRef

346. 346

     Alexander S. Goldfarb-Rumyantzev, Arsalan N. Habib, Bradley C. Baird, Lev L. Barenbaum, Alfred K. Cheung. (2007) The Association of Lipid-Modifying Medications With Mortality in Patients on Long-Term Peritoneal Dialysis. American Journal of Kidney Diseases 50:5, 791-802
     CrossRef

347. 347

     M. J. Alberts, B. Ovbiagele. (2007) Current strategies for ischemic stroke prevention: role of multimodal combination therapies. Journal of Neurology 254:10, 1414-1426
     CrossRef

348. 348

     Solveig Sakshaug, Kari Furu, Øystein Karlstad, Marit Rønning, Svetlana Skurtveit. (2007) Switching statins in Norway after new reimbursement policy ? a nationwide prescription study. British Journal of Clinical Pharmacology 64:4, 476-481
     CrossRef

349. 349

     R. Weber, H.C. Diener, M. Grond. (2007) Aktuelle Aspekte der Sekundärprophylaxe des ischämischen Schlaganfalls. Der Nervenarzt 78:10, 1138-1146
     CrossRef

350. 350

     (2007) Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia 50:11, 2289-2297
     CrossRef

351. 351

     Dara G. Jamieson. (2007) Secondary Prevention of Ischemic Stroke: Evolution from a Stepwise to a Risk Stratification Approach to Care. Disease Management 10:5, 273-284
     CrossRef

352. 352

     Peter M Rothwell, Matthew F Giles, Arvind Chandratheva, Lars Marquardt, Olivia Geraghty, Jessica NE Redgrave, Caroline E Lovelock, Lucy E Binney, Linda M Bull, Fiona C Cuthbertson, Sarah JV Welch, Shelley Bosch, Faye Carasco-Alexander, Louise E Silver, Sergei A Gutnikov, Ziyah Mehta. (2007) Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. The Lancet 370:9596, 1432-1442
     CrossRef

353. 353

     Jamal Mikdashi. (2007) Inflammation, dyslipidemia and risks of ischemic strokes in systemic lupus erythematosus. Future Lipidology 2:5, 489-493
     CrossRef

354. 354

     Ishwarlal Jialal, Sridevi Devaraj. (2007) Statin therapy in acute cardiovascular syndromes. Current Opinion in Lipidology 18:5, 610-612
     CrossRef

355. 355

     Howard N. Hodis, Wendy J. Mack. (2007) Postmenopausal hormone therapy in clinical perspective. Menopause 14:5, 944-957
     CrossRef

356. 356

     Kyle A Weant, Aaron M Cook. (2007) Potential Roles for Statins in Critically Ill Patients. Pharmacotherapy 27:9, 1279-1296
     CrossRef

357. 357

     William M. Landau. (2007) Pertinacious prescription of practice paradigms: The ethical burden of coercive clinical guidelines. Current Neurology and Neuroscience Reports 7:5, 355-358
     CrossRef

358. 358

     &NA;. (2007) FULL TEXT Chapter 1: Introduction. European Journal of Cardiovascular Prevention & Rehabilitation 14:Supplement 2, S2-S113
     CrossRef

359. 359

     Richard A. Bernstein. (2007) Statin therapy to prevent stroke in the elderly. Current Cardiovascular Risk Reports 1:4, 324-329
     CrossRef

360. 360

     F. Cohen Aubart, B. Hansel, J.-S. Hulot, P. Lechat, E. Bruckert. (2007) Avancées récentes et perspectives dans le traitement des dyslipidémies athérogènes. La Revue de Médecine Interne 28:8, 537-544
     CrossRef

361. 361

     Kosmas I. Paraskevas, Anthony S. Wierzbicki, D. P. Mikhailidis. (2007) METEOR: aiming at the stars for asymptomatic carotid artery atherosclerosis?*. International Journal of Clinical Practice 61:8, 1242-1246
     CrossRef

362. 362

     Kosmas I. Paraskevas, George Hamilton, Dimitri P. Mikhailidis. (2007) Statins: An essential component in the management of carotid artery disease. Journal of Vascular Surgery 46:2, 373-386.e9
     CrossRef

363. 363

     Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas. (2007) Atorvastatin Treatment for Men with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement. European Urology 52:2, 503-509
     CrossRef

364. 364

     Mathias Buttmann, Alexander Lorenz, Andreas Weishaupt, Peter Rieckmann. (2007) Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration. Journal of Neurochemistry 102:4, 1001-1008
     CrossRef

365. 365

     Emmanuel Touzé, Olivier Varenne, David Calvet, Jean-Louis Mas. (2007) Coronary risk stratification in patients with ischemic stroke or transient ischemic stroke attack. International Journal of Stroke 2:3, 177-183
     CrossRef

366. 366

     J David Spence. (2007) Stroke prevention in the high-risk patient. Expert Opinion on Pharmacotherapy 8:12, 1851-1859
     CrossRef

367. 367

     John B. Weigele, Robert A. Taylor, Scott E. Kasner. (2007) Current management of symptomatic intracranial stenosis: Medical versus endovascular therapy. Current Atherosclerosis Reports 9:4, 296-304
     CrossRef

368. 368

     Frauke Zipp, Sonia Waiczies, Orhan Aktas, Oliver Neuhaus, Bernhard Hemmer, Burkhard Schraven, Robert Nitsch, Hans-Peter Hartung. (2007) Impact of HMG-CoA reductase inhibition on brain pathology. Trends in Pharmacological Sciences 28:7, 342-349
     CrossRef

369. 369

     Larry B. Goldstein. (2007) Statins for stroke prevention. Current Atherosclerosis Reports 9:4, 305-311
     CrossRef

370. 370

     K. K. Ray, C. P. Cannon, E. Braunwald. (2007) Recent trials of lipid lowering. International Journal of Clinical Practice 61:7, 1145-1159
     CrossRef

371. 371

     Peter P. Toth, Chris J. Cadman. (2007) Implications of recent statin trials for primary care practice. Journal of Clinical Lipidology 1:3, 182-190
     CrossRef

372. 372

     Xavier Ustrell-Roig, Joaquín Serena-Leal. (2007) Ictus. Diagnóstico y tratamiento de las enfermedades cerebrovasculares. Revista Española de Cardiología 60:7, 753-769
     CrossRef

373. 373

     L. R. Erhardt, F. D. R. Hobbs. (2007) A global survey of physicians? perceptions on cholesterol management: the From The Heart study. International Journal of Clinical Practice 61:7, 1078-1085
     CrossRef

374. 374

     Juan F. Arenillas, Tomás Sobrino, José Castillo, Antoni Dávalos. (2007) The role of angiogenesis in damage and recovery from ischemic stroke. Current Treatment Options in Cardiovascular Medicine 9:3, 205-212
     CrossRef

375. 375

     Mai N Nguyen-Huynh, S Claiborne Johnston. (2007) Evaluation and management of transient ischemic attack: an important component of stroke prevention. Nature Clinical Practice Cardiovascular Medicine 4:6, 310-318
     CrossRef

376. 376

     Oliver Neuhaus, Hans-Peter Hartung. (2007) Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Review of Neurotherapeutics 7:5, 547-556
     CrossRef

377. 377

     B. Iglseder. (2007) Jeder einzelne Risikofaktor zählt!. focus neurogeriatrie 1:1, 14-15
     CrossRef

378. 378

     Julia Ferrari. (2007) Schlaganfallmanagement in der Geriatrie. focus neurogeriatrie 1:1, 35-40
     CrossRef

379. 379

     Pierre Amarenco. (2007) Lipid lowering and recurrent stroke: a definitive answer?. International Journal of Stroke 2:2, 111-113
     CrossRef

380. 380

     Jacob S. Elkins. (2007) Atherosclerosis and dementia: Leading by association. Annals of Neurology 61:5, 377-379
     CrossRef

381. 381

     Mária Tünde Magyar, Dániel Bereczki. (2007) Cholesterol and the cerebral circulation. Future Lipidology 2:2, 211-228
     CrossRef

382. 382

     Jessica N Redgrave, Peter M Rothwell. (2007) Asymptomatic carotid stenosis: what to do. Current Opinion in Internal Medicine 6:2, 156-162
     CrossRef

383. 383

     Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2007) The Year in Atherothrombosis. Journal of the American College of Cardiology 49:16, 1740-1749
     CrossRef

384. 384

     Graeme J Hankey. (2007) Clinical update: management of stroke. The Lancet 369:9570, 1330-1332
     CrossRef

385. 385

     Eddie Vos. (2007) Canadian Journal of Cardiology 23:5, 397-398
     CrossRef

386. 386

     Bruce Ovbiagele. (2007) Statin therapy after stroke or transient ischemic attack—a new weapon in our secondary stroke prevention arsenal?. Nature Clinical Practice Neurology 3:3, 130-131
     CrossRef

387. 387

     Kurt Samson. (2007) Low LDL Cholesterol May Raise Bleeding Risk After Thrombolysis for Ischemic Stroke Patients, Study Finds. Neurology Today 7:5, 46-47
     CrossRef

388. 388

     Doreen DeFaria Yeh, David D Waters. (2007) The SPARCL study: extending the indications of statin therapy for stroke?. Nature Clinical Practice Cardiovascular Medicine 4:3, 128-129
     CrossRef

389. 389

     (2007) Scientific Surgery. British Journal of Surgery 94:3, 388-388
     CrossRef

390. 390

     José Tuñón, José Luis Martín-Ventura, Luis Miguel Blanco-Colio, Jesús Egido. (2007) Mechanisms of action of statins in stroke. Expert Opinion on Therapeutic Targets 11:3, 273-278
     CrossRef

391. 391

     Norra MacReady. (2007) James C. Grotta. Neurology Today 7:6, 28-29
     CrossRef

392. 392

     Nils Butte, B.W. Böttiger, P. Teschendorf. (2007) Perioperative Kardioprotektion. Der Anaesthesist 56:3, 285-298
     CrossRef

393. 393

     Fernando Alfonso, Javier Segovia, Magda Heras, Javier Bermejo. (2007) Patología arterial no coronaria: ¿de interés para el cardiólogo?. Revista Española de Cardiología 60:2, 179-183
     CrossRef

394. 394

     Takashi Miida, Akihiro Takahashi, Takeshi Ikeuchi. (2007) Prevention of stroke and dementia by statin therapy: Experimental and clinical evidence of their pleiotropic effects. Pharmacology & Therapeutics 113:2, 378-393
     CrossRef

395. 395

     Carlos Lahoz, José M. Mostaza. (2007) La Aterosclerosis como enfermedad sistémica. Revista Española de Cardiología 60:2, 184-195
     CrossRef

396. 396

     Tudor G. Jovin, Rishi Gupta, Michael B. Horowitz. (2007) Management of symptomatic intracranial atherosclerotic disease. Current Cardiology Reports 9:1, 32-40
     CrossRef

397. 397

     Anne L. Abbott, Christopher F. Bladin, Christopher R. Levi, Brian R. Chambers. (2007) What should we do with asymptomatic carotid stenosis?. International Journal of Stroke 2:1, 27-39
     CrossRef

398. 398

     G. Erez, E. Leitersdorf. (2007) The Rationale for Using HMG-CoA Reductase Inhibitors (‘Statins’) in Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery 33:2, 192-201
     CrossRef

399. 399

     Masayasu Matsumoto. (2007) Recent advances in Stroke Medicine. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 44:4, 422-424
     CrossRef

400. 400

     Asterios Karagiannis, Dimitri P. Mikhailidis, Konstantinos Tziomalos, Maria Sileli, Savvas Savvatianos, Anna Kakafika, Thomas Gossios, Napoleon Krikis, Irene Moschou, Michael Xochellis, Vassilios G. Athyros. (2007) Serum Uric Acid as an Independent Predictor of Early Death After Acute Stroke. Circulation Journal 71:7, 1120-1127
     CrossRef

401. 401

     Philip R. Liebson. (2007) DREAM and SPARCL. Preventive Cardiology 10:1, 48-51
     CrossRef

402. 402

     A. Verma. (2007) High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. Yearbook of Neurology and Neurosurgery 2007, 7-10
     CrossRef

403. 403

     Carlos Lahoz, José M. Mostaza. (2007) Atherosclerosis As a Systemic Disease. Revista Española de Cardiología (English Edition) 60:2, 184-195
     CrossRef

404. 404

     Maurizio Paciaroni, Michael Hennerici, Giancarlo Agnelli, Julien Bogousslavsky. (2007) Statins and Stroke Prevention. Cerebrovascular Diseases 24:2-3, 170-182
     CrossRef

405. 405

     Achille Gaspardone, Marcello Arca. (2007) Atorvastatin. Drugs 67:Supplement 1, 55-62
     CrossRef

406. 406

     Xavier Ustrell-Roig, Joaquín Serena-Leal. (2007) Stroke. Diagnosis and Therapeutic Management of Cerebrovascular Disease. Revista Española de Cardiología (English Edition) 60:7, 753-769
     CrossRef

407. 407

     Bengt Fellstr&ouml;m, Hallvard Holdaas, Alan G. Jardine, Helen Rose, Roland Schmieder, Wim Wilpshaar, Faiez Zannad. (2007) Effect of Rosuvastatin on Outcomes in Chronic Haemodialysis Patients: Baseline Data from the AURORA Study. Kidney and Blood Pressure Research 30:5, 314-322
     CrossRef

408. 408

     Michael D Hill. (2007) Stroke: the dashed hopes of neuroprotection. The Lancet Neurology 6:1, 2-3
     CrossRef

409. 409

     Eric R. Bates, Joseph D. Babb, Donald E. Casey, Christopher U. Cates, Gary R. Duckwiler, Ted E. Feldman, William A. Gray, Kenneth Ouriel, Eric D. Peterson, Kenneth Rosenfield, John H. Rundback, Robert D. Safian, Michael A. Sloan, Christopher J. White, Robert A. Harrington, Jonathan Abrams, Jeffrey L. Anderson, Eric R. Bates, Mark J. Eisenberg, Cindy L. Grines, Mark A. Hlatky, Robert C. Lichtenberg, Jonathan R. Lindner, Gerald M. Pohost, Richard S. Schofield, Samuel J. Shubrooks, James H. Stein, Cynthia M. Tracy, Robert A. Vogel, Deborah J. Wesley. (2007) ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting. Journal of the American College of Cardiology 49:1, 126-170
     CrossRef

410. 410

     B. Fuentes, M.A. Ortega-Casarrubios, P. Mart&iacute;nez, E. D&iacute;ez-Tejedor. (2007) Action on Vascular Risk Factors: Importance of Blood Pressure and Lipid Lowering in Stroke Secondary Prevention. Cerebrovascular Diseases 24:1, 96-106
     CrossRef

411. 411

     Gy??rgy Paragh, L??szlo M??rk, K??roly Z??molyi, Gyula Pados, P??ter Ofner. (2007) Lipid-Modifying Therapy and Attainment of Cholesterol Goals in Hungary. Clinical Drug Investigation 27:9, 647-660
     CrossRef

412. 412

     Fernando Alfonso, Javier Segovia, Magda Heras, Javier Bermejo. (2007) Non-Coronary Arterial Disease: of Interest to Cardiologists?. Revista Española de Cardiología (English Edition) 60:2, 179-183
     CrossRef

413. 413

     Lina Badimon, Gemma Vilahur. (2007) Platelets, Arterial Thrombosis and Cerebral Ischemia. Cerebrovascular Diseases 24:1, 30-39
     CrossRef

414. 414

     J.J. Provencio. (2007) High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. Yearbook of Critical Care Medicine 2007, 263-264
     CrossRef

415. 415

     Ralph L Sacco, Ji Y Chong, Shyam Prabhakaran, Mitchell SV Elkind. (2007) Experimental treatments for acute ischaemic stroke. The Lancet 369:9558, 331-341
     CrossRef

416. 416

     Pierre Fayad. (2006) Secondary prevention measures after a stroke—should they target stroke or heart disease?. Nature Clinical Practice Neurology 2:12, 646-647
     CrossRef

417. 417

     Stephen D Wiviott, Christopher P Cannon. (2006) The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Current Opinion in Lipidology 17:6, 626-630
     CrossRef

418. 418

     (2006) Statin Therapy after Stroke or Transient Ischemic Attack. New England Journal of Medicine 355:22, 2368-2371
     Full Text

419. 419

     Richard A. Bernstein. (2006) Cholesterol lowering to prevent stroke: Who, when, and how?. Current Treatment Options in Neurology 8:6, 496-502
     CrossRef

420. 420

     Mitchell S. V. Elkind. (2006) Statins as acute-stroke treatment. International Journal of Stroke 1:4, 224-225
     CrossRef

421. 421

     Robert A Taylor, Scott E Kasner. (2006) Treatment of intracranial arterial stenosis. Expert Review of Neurotherapeutics 6:11, 1685-1694
     CrossRef

422. 422

     David D. Waters, John C. LaRosa, Philip Barter, Jean-Charles Fruchart, Antonio M. Gotto, Roddy Carter, Andrei Breazna, John J.P. Kastelein, Scott M. Grundy. (2006) Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study. Journal of the American College of Cardiology 48:9, 1793-1799
     CrossRef

423. 423

     Graeme J Hankey. (2006) Statins after transient ischaemic attack and ischaemic stroke. The Lancet Neurology 5:10, 810-812
     CrossRef

424. 424

     Kurt Samson. (2006) MAJOR STATIN STUDY FINDS FEWER SECOND STROKES IN TREATED PATIENTS. Neurology Today 6:18, 1
     CrossRef

425. 425

     Kent, David M., . (2006) Stroke — An Equal Opportunity for the Initiation of Statin Therapy. New England Journal of Medicine 355:6, 613-615
     Full Text

Letters